Exact Mass: 394.2847

Exact Mass Matches: 394.2847

Found 500 metabolites which its exact mass value is equals to given mass value 394.2847, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Ergosta-5,7,22,24(28)-tetraen-3beta-ol

(3S,10R,13R)-10,13-dimethyl-17-[(E,2R)-6-methyl-5-methylidenehept-3-en-2-yl]-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol

C28H42O (394.3235)


A 3beta-sterol having double bonds in the 5-, 7- and 22-positions and a methylene group at position 24.

   

Tylactone

Tylactone; Protylonolide

C23H38O5 (394.2719)


A 16-membererd macrolide that is the aglycone of the antibiotic 5-O-beta-D-mycaminosyltylactone.

   

DHT benzoate

Dihydrotestosterone benzoate

C26H34O3 (394.2508)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones

   

Petromyzonol

3α,7α,12α,24-tetrahydroxy-5α-cholane

C24H42O4 (394.3083)


   

3'-Methoxy-[6]-Gingerdiol 3,5-diacetate

3-(acetyloxy)-1-(3,4-dimethoxyphenyl)decan-5-yl acetate

C22H34O6 (394.2355)


3-Methoxy-[6]-Gingerdiol 3,5-diacetate is a carboxylic ester. 3-Methoxy-[6]-Gingerdiol 3,5-diacetate is a natural product found in Zingiber officinale with data available. 3-Methoxy-[6]-Gingerdiol 3,5-diacetate is found in ginger. 3-Methoxy-[6]-Gingerdiol 3,5-diacetate is a constituent of ginger (Zingiber officinale) rhizomes. Constituent of ginger (Zingiber officinale) rhizomes. 3-Methoxy-[6]-Gingerdiol 3,5-diacetate is found in herbs and spices and ginger.

   

(3beta,22E,24R)-Ergosta-4,6,8(14),22-tetraen-3-ol

14-[(3E)-5,6-dimethylhept-3-en-2-yl]-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-6,8,10-trien-5-ol

C28H42O (394.3235)


(3beta,22E,24R)-Ergosta-4,6,8(14),22-tetraen-3-ol is found in mushrooms. (3beta,22E,24R)-Ergosta-4,6,8(14),22-tetraen-3-ol is a constituent of Marasmius oreades (fairy ring mushroom). Constituent of Marasmius oreades (fairy ring mushroom). (3beta,22E,24R)-Ergosta-4,6,8(14),22-tetraen-3-ol is found in mushrooms.

   

(3b,6b,8b,12a)-8,12-Epoxy-7(11)-eremophilene-6-angeloyloxy-8,12-dimethoxy-3-ol

6-Hydroxy-2,9a-dimethoxy-3,4a,5-trimethyl-2H,4H,4ah,5H,6H,7H,8H,8ah,9H,9ah-naphtho[2,3-b]furan-4-yl (2E)-2-methylbut-2-enoic acid

C22H34O6 (394.2355)


(3b,6b,8b,12a)-8,12-Epoxy-7(11)-eremophilene-6-angeloyloxy-8,12-dimethoxy-3-ol is found in green vegetables. (3b,6b,8b,12a)-8,12-Epoxy-7(11)-eremophilene-6-angeloyloxy-8,12-dimethoxy-3-ol is a constituent of Petasites japonicus (sweet coltsfoot) Constituent of Petasites japonicus (sweet coltsfoot). (3b,6b,8b,12a)-8,12-Epoxy-7(11)-eremophilene-6-angeloyloxy-8,12-dimethoxy-3-ol is found in green vegetables.

   

7,8-Dehydro-beta-micropteroxanthin

4-[(3E,5E,7E,9E,11E)-15-hydroxy-3,7,12-trimethylpentadeca-3,5,7,9,11-pentaen-1-yn-1-yl]-3,5,5-trimethylcyclohex-3-en-1-ol

C27H38O2 (394.2872)


7,8-Dehydro-beta-micropteroxanthin is found in fishes. 7,8-Dehydro-beta-micropteroxanthin is isolated from integuments of black bass Micropterus salmoides. Isolated from integuments of black bass Micropterus salmoides. 7,8-Dehydro-beta-micropteroxanthin is found in fishes.

   

LysoPA(P-16:0/0:0)

[(2R)-3-[(1Z)-hexadec-1-en-1-yloxy]-2-hydroxypropoxy]phosphonic acid

C19H39O6P (394.2484)


1-(1Z-hexadecenyl)-sn-glycero-3-phosphate is an intermediate of ether lipid metabolism. Ether lipids are lipids in which one or more of the carbon atoms on glycerol is bonded to an alkyl chain via an ether linkage, as opposed to the usual ester linkage. 1-(1Z-hexadecenyl)-sn-glycero-3-phosphate is irreversibly produced from 1-(1Z-hexadecenyl)-sn-glycero-3-phosphoethanolamine via the enzyme alkylglycerophosphoethanolamine phosphodiesterase (EC: 3.1.4.39). Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. 1-(1Z-hexadecenyl)-sn-glycero-3-phosphate is an intermediate of ether lipid metabolism. Ether lipids are lipids in which one or more of the carbon atoms on glycerol is bonded to an alkyl chain via an ether linkage, as opposed to the usual ester linkage.

   

11-Hydroxyeicosatetraenoate glyceryl ester

1,3-Dihydroxypropan-2-yl (5Z,8Z,11S,12E,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoic acid

C23H38O5 (394.2719)


11(R)-HETE is produced from arachidonic acid by both COX-1 and COX-2 (cyclooxygenases). Using a model of intestinal epithelial cells that express the COX-2 permanently, 11(R)-HETE is produced upon stimulation. However, 11(R)-HETE is not detected in intact cells. Endothelial cells release several factors which influence vascular tone, leukocyte function and platelet aggregation; 11(R)-HETE is one of these factors. (PMID: 15964853, 8555273) [HMDB] 11(R)-HETE is produced from arachidonic acid by both COX-1 and COX-2 (cyclooxygenases). Using a model of intestinal epithelial cells that express the COX-2 permanently, 11(R)-HETE is produced upon stimulation. However, 11(R)-HETE is not detected in intact cells. Endothelial cells release several factors which influence vascular tone, leukocyte function and platelet aggregation; 11(R)-HETE is one of these factors. (PMID: 15964853, 8555273).

   

2-(14,15-Epoxyeicosatrienoyl) Glycerol

1,3-dihydroxypropan-2-yl (5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoate

C23H38O5 (394.2719)


2-(14,15-Epoxyeicosatrienoyl) glycerol, or 2-14,15-EG, is a cytochrome P450 metabolite of 2-arachidonoyl glycerol in the kidney (PMID: 17283047). 2-Arachidonoyl glycerol (2-AG) is an endogenous central cannabinoid (CB1) receptor agonist that is present at relatively high levels in the central nervous system (PMID: 9285589, 9915812, 9650580). 2-AG is hydrolyzed by the enzyme monoacylglycerol lipase, terminating its biological activity, and metabolism by cyclooxygenase-2 and lipoxygenases has been documented (PMID: 12136125, 12052037). The related endocannabinoid, 2-arachidonoyl ethanolamide (AEA), can be metabolized by cytochrome P450 (CYP450) enzymes in human liver and kidney to a number of epoxy-ethanolamide derivatives (PMID: 17272674). 2-14,15-EG is a potent mitogen for renal epithelial cells, increasing DNA synthesis in LLCPKcl4 cells at concentrations as low as 100 nM and doubling cell proliferation rates at 1 µM (PMID: 17283047). In these cells, 2-14,15-EG activates the metalloprotease ADAM17, which cleaves proTGF-α and releases TGF-α as a ligand that initiates the EGFR-ERK signalling pathway. 2-Arachidonoyl glycerol (2-AG) is an endogenous central cannabinoid (CB1) receptor agonist that is present at relatively high levels in the central nervous system.1,2,3 2-AG is hydrolyzed by the enzyme monoacylglycerol lipase, terminating its biological activity, and metabolism by cyclooxygenase-2 and lipoxygenases has been documented.4,5 The related endocannabinoid, 2-arachidonoyl ethanolamide (AEA), can be metabolized by cytochrome P450 (CYP450) enzymes in human liver and kidney to a number of epoxy-ethanolamide derivatives.6 2-14,15-EG is a novel CYP450 metabolite of 2-AG in the kidney.7 2-14,15-EG is a potent mitogen for renal epithelial cells, increasing DNA synthesis in LLCPKcl4 cells at concentrations as low as 100 nM and doubling cell proliferation rates at 1 ?M.7 In these cells, 2-14,15-EG activates the metalloprotease ADAM17, which cleaves proTGF-α and releases TGF-α as a ligand that initiates the EGFR-ERK signalling pathway. [HMDB]

   

Dehydroergosterol

14-(5,6-dimethylhept-3-en-2-yl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-1(17),7,9-trien-5-ol

C28H42O (394.3235)


   

gemeprost

methyl 7-[3-hydroxy-2-(3-hydroxy-4,4-dimethyloct-1-en-1-yl)-5-oxocyclopentyl]hept-2-enoate

C23H38O5 (394.2719)


   

Norcholic acid

3-{5,9,16-trihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl}butanoic acid

C23H38O5 (394.2719)


Norcholic acid is a normal minorbile C23 bile acid having four side chain and exsits in human urine and meconium. Norcholic acid can become prominent under certain pathological conditions. Norcholic acid is efficiently absorbed from intestine and quickly excreted into the bile but not into urine[1].

   

1,6-Bis(cyclohexyloximinocarbonyl)hexane

N-[6-({[(cyclohexylideneamino)oxy](hydroxy)methylidene}amino)hexyl][(cyclohexylideneamino)oxy]carboximidate

C20H34N4O4 (394.258)


   

Stanolone benzoate

2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl benzoate

C26H34O3 (394.2508)


   

MG(20:3(5Z,8Z,11Z)-O(14R,15S)/0:0/0:0)

(2S)-2,3-Dihydroxypropyl (5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoic acid

C23H38O5 (394.2719)


MG(20:3(5Z,8Z,11Z)-O(14R,15S)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(20:3(5Z,8Z,14Z)-O(11S,12R)/0:0/0:0)

(2S)-2,3-Dihydroxypropyl (5Z,8Z)-10-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}deca-5,8-dienoic acid

C23H38O5 (394.2719)


MG(20:3(5Z,8Z,14Z)-O(11S,12R)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(20:3(5Z,11Z,14Z)-O(8,9)/0:0/0:0)

(2S)-2,3-Dihydroxypropyl (5Z)-7-{3-[(5Z)-undeca-2,5-dien-1-yl]oxiran-2-yl}hept-5-enoic acid

C23H38O5 (394.2719)


MG(20:3(5Z,11Z,14Z)-O(8,9)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(20:3(8Z,11Z,14Z)-O(5,6)/0:0/0:0)

(2S)-2,3-Dihydroxypropyl 4-{3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trien-1-yl]oxiran-2-yl}butanoic acid

C23H38O5 (394.2719)


MG(20:3(8Z,11Z,14Z)-O(5,6)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(20:4(5Z,8Z,11Z,14Z)-OH(20)/0:0/0:0)

(2S)-2,3-dihydroxypropyl (5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoate

C23H38O5 (394.2719)


MG(20:4(5Z,8Z,11Z,14Z)-OH(20)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(20:4(6E,8Z,11Z,14Z)-OH(5S)/0:0/0:0)

(2S)-2,3-Dihydroxypropyl (5S,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoic acid

C23H38O5 (394.2719)


MG(20:4(6E,8Z,11Z,14Z)-OH(5S)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(20:4(5Z,8Z,11Z,14Z)-OH(19S)/0:0/0:0)

(2S)-2,3-dihydroxypropyl (5Z,8Z,11Z,14Z,19R)-19-hydroxyicosa-5,8,11,14-tetraenoate

C23H38O5 (394.2719)


MG(20:4(5Z,8Z,11Z,14Z)-OH(19S)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(20:4(5Z,8Z,11Z,14Z)-OH(18R)/0:0/0:0)

(2S)-2,3-dihydroxypropyl (5Z,8Z,11Z,14Z,18S)-18-hydroxyicosa-5,8,11,14-tetraenoate

C23H38O5 (394.2719)


MG(20:4(5Z,8Z,11Z,14Z)-OH(18R)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(20:4(5Z,8Z,11Z,14Z)-OH(17)/0:0/0:0)

(2S)-2,3-dihydroxypropyl (5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoate

C23H38O5 (394.2719)


MG(20:4(5Z,8Z,11Z,14Z)-OH(17)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(20:4(5Z,8Z,11Z,14Z)-OH(16R)/0:0/0:0)

(2S)-2,3-dihydroxypropyl (5Z,8Z,11Z,14Z,16S)-16-hydroxyicosa-5,8,11,14-tetraenoate

C23H38O5 (394.2719)


MG(20:4(5Z,8Z,11Z,14Z)-OH(16R)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(20:4(5Z,8Z,11Z,13E)-OH(15S)/0:0/0:0)

(2S)-2,3-Dihydroxypropyl (5Z,8Z,11Z,13E,15R)-15-hydroxyicosa-5,8,11,13-tetraenoic acid

C23H38O5 (394.2719)


MG(20:4(5Z,8Z,11Z,13E)-OH(15S)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(20:4(5Z,8Z,10E,14Z)-OH(12S)/0:0/0:0)

(2S)-2,3-dihydroxypropyl (5Z,8Z,10E,12R,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoate

C23H38O5 (394.2719)


MG(20:4(5Z,8Z,10E,14Z)-OH(12S)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(20:4(5E,8Z,12Z,14Z)-OH(11R)/0:0/0:0)

(2S)-2,3-Dihydroxypropyl (5E,8Z,11S,12Z,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoic acid

C23H38O5 (394.2719)


MG(20:4(5E,8Z,12Z,14Z)-OH(11R)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(20:4(5Z,7E,11Z,14Z)-OH(9)/0:0/0:0)

(2S)-2,3-Dihydroxypropyl (5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoic acid

C23H38O5 (394.2719)


MG(20:4(5Z,7E,11Z,14Z)-OH(9)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/20:3(5Z,8Z,14Z)-O(11S,12R)/0:0)

1,3-dihydroxypropan-2-yl (5Z,8Z)-10-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}deca-5,8-dienoate

C23H38O5 (394.2719)


MG(0:0/20:3(5Z,8Z,14Z)-O(11S,12R)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/20:3(5Z,11Z,14Z)-O(8,9)/0:0)

1,3-Dihydroxypropan-2-yl (5Z)-7-{3-[(2Z,5Z)-undeca-2,5-dien-1-yl]oxiran-2-yl}hept-5-enoic acid

C23H38O5 (394.2719)


MG(0:0/20:3(5Z,11Z,14Z)-O(8,9)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/20:3(8Z,11Z,14Z)-O(5,6)/0:0)

1,3-Dihydroxypropan-2-yl 4-{3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trien-1-yl]oxiran-2-yl}butanoic acid

C23H38O5 (394.2719)


MG(0:0/20:3(8Z,11Z,14Z)-O(5,6)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/20:4(5Z,8Z,11Z,14Z)-OH(20)/0:0)

1,3-Dihydroxypropan-2-yl (5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoic acid

C23H38O5 (394.2719)


MG(0:0/20:4(5Z,8Z,11Z,14Z)-OH(20)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/20:4(6E,8Z,11Z,14Z)-OH(5S)/0:0)

1,3-Dihydroxypropan-2-yl (5R,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoic acid

C23H38O5 (394.2719)


MG(0:0/20:4(6E,8Z,11Z,14Z)-OH(5S)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)/0:0)

1,3-Dihydroxypropan-2-yl (5Z,8Z,11Z,14Z,19S)-19-hydroxyicosa-5,8,11,14-tetraenoic acid

C23H38O5 (394.2719)


MG(0:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)/0:0)

1,3-Dihydroxypropan-2-yl (5Z,8Z,11Z,14Z,18R)-18-hydroxyicosa-5,8,11,14-tetraenoic acid

C23H38O5 (394.2719)


MG(0:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/20:4(5Z,8Z,11Z,14Z)-OH(17)/0:0)

1,3-Dihydroxypropan-2-yl (5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoic acid

C23H38O5 (394.2719)


MG(0:0/20:4(5Z,8Z,11Z,14Z)-OH(17)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)/0:0)

1,3-Dihydroxypropan-2-yl (5Z,8Z,11Z,14Z,16R)-16-hydroxyicosa-5,8,11,14-tetraenoic acid

C23H38O5 (394.2719)


MG(0:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/20:4(5Z,8Z,11Z,13E)-OH(15S)/0:0)

1,3-dihydroxypropan-2-yl (5Z,8Z,11Z,13E,15S)-15-hydroxyicosa-5,8,11,13-tetraenoate

C23H38O5 (394.2719)


MG(0:0/20:4(5Z,8Z,11Z,13E)-OH(15S)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/20:4(5Z,8Z,10E,14Z)-OH(12S)/0:0)

1,3-dihydroxypropan-2-yl (5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoate

C23H38O5 (394.2719)


MG(0:0/20:4(5Z,8Z,10E,14Z)-OH(12S)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/20:4(5E,8Z,12Z,14Z)-OH(11R)/0:0)

1,3-Dihydroxypropan-2-yl (5E,8Z,11R,12Z,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoic acid

C23H38O5 (394.2719)


MG(0:0/20:4(5E,8Z,12Z,14Z)-OH(11R)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/20:4(5Z,7E,11Z,14Z)-OH(9)/0:0)

1,3-Dihydroxypropan-2-yl (5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoic acid

C23H38O5 (394.2719)


MG(0:0/20:4(5Z,7E,11Z,14Z)-OH(9)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

Methyl-[12]-gingerdiol

1-(3,4-dimethoxyphenyl)hexadecane-3,5-diol

C24H42O4 (394.3083)


Methyl-[12]-gingerdiol is a member of the class of compounds known as long-chain fatty alcohols. Long-chain fatty alcohols are fatty alcohols that have an aliphatic tail of 13 to 21 carbon atoms. Methyl-[12]-gingerdiol is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). Methyl-[12]-gingerdiol can be found in ginger, which makes methyl-[12]-gingerdiol a potential biomarker for the consumption of this food product.

   

Bisdihydrotrifarin

Bisdihydrotrifarin

C24H42O4 (394.3083)


   

9-Deoxyforskolin

9-Deoxyforskolin

C22H34O6 (394.2355)


   

MCULE-5539918199

MCULE-5539918199

C28H42O (394.3235)


   
   

Asbestinin 24

Asbestinin 24

C23H38O5 (394.2719)


   

FT-0774027

FT-0774027

C28H42O (394.3235)


   

Albopilosin B

Albopilosin B

C22H34O6 (394.2355)


   

Leopersin B

Leopersin B

C22H34O6 (394.2355)


   
   

nor-Spiculoic acid A

(+)-nor-Spiculoic acid A

C26H34O3 (394.2508)


   

Melissoidesin I

Melissoidesin I

C22H34O6 (394.2355)


   

Diacarnoxide B

Diacarnoxide B

C24H42O4 (394.3083)


   

Pregnacetal

Pregnacetal

C23H38O5 (394.2719)


   

Sargaquinone

Sargaquinone

C27H38O2 (394.2872)


   
   

17-Acetoxyacanthoaustralide

17-Acetoxyacanthoaustralide

C22H34O6 (394.2355)


   

Otostegin B

Otostegin B

C22H34O6 (394.2355)


   

Heteranthin

Methyl-3-oxo-12-apo-epsilon,psi-caroten-12-oate

C26H34O3 (394.2508)


   

Epoxycladine C

Epoxycladine C

C22H34O6 (394.2355)


   

Melissoidesin P

Melissoidesin P

C22H34O6 (394.2355)


   

seco-Asbestinin B

seco-Asbestinin B

C22H34O6 (394.2355)


   

2-(14,15-epoxyeicosatrienoyl)glycerol

2-(14,15-epoxyeicosatrienoyl)glycerol

C23H38O5 (394.2719)


   

Sumilizer GM

Sumilizer GM

C26H34O3 (394.2508)


   

grayanotoxin IV

grayanotoxin IV

C22H34O6 (394.2355)


   
   

19-acetoxy-20-hydroxygeranylnerol-17-acid

19-acetoxy-20-hydroxygeranylnerol-17-acid

C22H34O6 (394.2355)


   

1-acetoxy-6,7-epoxy-19-hydroxy-12-oxo-smallantha-2Z,13E-diene

1-acetoxy-6,7-epoxy-19-hydroxy-12-oxo-smallantha-2Z,13E-diene

C23H38O5 (394.2719)


   

10-acetoxy-7,8-dimethylpodopyrone

10-acetoxy-7,8-dimethylpodopyrone

C23H38O5 (394.2719)


   

24-norspiculoic acid A

24-norspiculoic acid A

C26H34O3 (394.2508)


   

(rel 5S,6R,8R,9R,10S,13S,15R)-6-acetoxy-9,13;15,16-diepoxy-15-methoxylabdane|(rel-5S,6R,8R,9R,10S,13S,15R)-6-acetoxy-9,13;15,16-diepoxy-15-methoxylabdane

(rel 5S,6R,8R,9R,10S,13S,15R)-6-acetoxy-9,13;15,16-diepoxy-15-methoxylabdane|(rel-5S,6R,8R,9R,10S,13S,15R)-6-acetoxy-9,13;15,16-diepoxy-15-methoxylabdane

C23H38O5 (394.2719)


   

16beta-O-methylnigakihemiacetal C|Nigakihemiacetal F

16beta-O-methylnigakihemiacetal C|Nigakihemiacetal F

C22H34O6 (394.2355)


   
   

SCHEMBL17867116

SCHEMBL17867116

C20H34N4O4 (394.258)


   

Antibiotic A 40104B

Antibiotic A 40104B

C22H34O6 (394.2355)


   

4beta-acetoxy-11-hydroxy-3beta-(2-methylbutyryloxy)-eudesm-6-en-8-one

4beta-acetoxy-11-hydroxy-3beta-(2-methylbutyryloxy)-eudesm-6-en-8-one

C22H34O6 (394.2355)


   

ergosta-5,7,14,22t-tetraen-3beta-ol

ergosta-5,7,14,22t-tetraen-3beta-ol

C28H42O (394.3235)


   

1-acetyl-5-angeloyl lapiferol|10alpha-acetoxy-6alpha-angeloyloxy-8alpha,9alpha-epoxy-trans-caxotan-4beta-ol|6alpha-angeloyl-10alpha-acetyl-8,9-epoxy-jaeschkeanadiol|lapiferin

1-acetyl-5-angeloyl lapiferol|10alpha-acetoxy-6alpha-angeloyloxy-8alpha,9alpha-epoxy-trans-caxotan-4beta-ol|6alpha-angeloyl-10alpha-acetyl-8,9-epoxy-jaeschkeanadiol|lapiferin

C22H34O6 (394.2355)


   

13(E)-8alpha-hydroxy-labd-13-en-15-ol malonate

13(E)-8alpha-hydroxy-labd-13-en-15-ol malonate

C23H38O5 (394.2719)


   

(2E,6E,10E)-2-methyl-(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl)benzoquinone|2-methyl-5-<(E,E,E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl>benzo-1,4-quinone

(2E,6E,10E)-2-methyl-(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl)benzoquinone|2-methyl-5-<(E,E,E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl>benzo-1,4-quinone

C27H38O2 (394.2872)


   

Apo-beta-carotin-3,10-diol|Galloxanthin

Apo-beta-carotin-3,10-diol|Galloxanthin

C27H38O2 (394.2872)


   

4-hydroxy-2-octadecanoylcyclohexane-1,3-dione|proctorione B

4-hydroxy-2-octadecanoylcyclohexane-1,3-dione|proctorione B

C24H42O4 (394.3083)


   

6alpha-hydroxy-17-acetoxygrindelic acid

6alpha-hydroxy-17-acetoxygrindelic acid

C22H34O6 (394.2355)


   

palmadorin C

palmadorin C

C23H38O5 (394.2719)


   

18-acetyl-7alpha-hydroxy-methyltrineracetal

18-acetyl-7alpha-hydroxy-methyltrineracetal

C23H38O5 (394.2719)


   

9,10-epoxy-6alpha-O-tigloyl-7alphaH-8beta-O-acetylgermacra-3(4)E-en-5beta-ol|trijugin C

9,10-epoxy-6alpha-O-tigloyl-7alphaH-8beta-O-acetylgermacra-3(4)E-en-5beta-ol|trijugin C

C22H34O6 (394.2355)


   

Inflexarabdonin F

Inflexarabdonin F

C22H34O6 (394.2355)


   

(3alpha, 22E)-1, 6-Cyclo-1, 10-secoergosta-5, 7, 9, 22-tetraen-3-ol|1(10-6)abeo-ergosta-5,7,9,22-tetraen-3alpha-ol

(3alpha, 22E)-1, 6-Cyclo-1, 10-secoergosta-5, 7, 9, 22-tetraen-3-ol|1(10-6)abeo-ergosta-5,7,9,22-tetraen-3alpha-ol

C28H42O (394.3235)


   

tanyolide A

tanyolide A

C22H34O6 (394.2355)


   

isolancerotetrol 5-isovalerate

isolancerotetrol 5-isovalerate

C23H38O5 (394.2719)


   

(2R)-6-(2-acetoxytridecyl)-5-hydroxy-2-methoxy-1,4-benzoquinone

(2R)-6-(2-acetoxytridecyl)-5-hydroxy-2-methoxy-1,4-benzoquinone

C22H34O6 (394.2355)


   

16,17-dihydrorostronol F

16,17-dihydrorostronol F

C22H34O6 (394.2355)


   

methyl 3alpha-acetoxy-15-hydroxy-labd-8(17)-en-19-oate

methyl 3alpha-acetoxy-15-hydroxy-labd-8(17)-en-19-oate

C23H38O5 (394.2719)


   

(3E,7E,11E)-2,7-dimethyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-2H-chromen-6-ol|2,7-dimethyl-2-((E,E)-4,8,12-trimethyltrideca-3,7,11-trienyl)-2H-1-benzopyran-6-ol|2,7-dimethyl-2-<(E,E)-4,8,12-trimethyltrideca-3,7,11-trienyl>-2H-1-benzopyran-6-ol

(3E,7E,11E)-2,7-dimethyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-2H-chromen-6-ol|2,7-dimethyl-2-((E,E)-4,8,12-trimethyltrideca-3,7,11-trienyl)-2H-1-benzopyran-6-ol|2,7-dimethyl-2-<(E,E)-4,8,12-trimethyltrideca-3,7,11-trienyl>-2H-1-benzopyran-6-ol

C27H38O2 (394.2872)


   

(S)-carduusyne-C ethyl ester

(S)-carduusyne-C ethyl ester

C26H34O3 (394.2508)


   

9,10-epoxy-5beta-O-tigloyl-7alphaH-8beta-O-acetylgermacra-3(4)E-en-6alpha-ol|trijugin A

9,10-epoxy-5beta-O-tigloyl-7alphaH-8beta-O-acetylgermacra-3(4)E-en-6alpha-ol|trijugin A

C22H34O6 (394.2355)


   

(1R,2S,5R,6S)-1-((1S,2E,4S,6E)-1,4-dihydroxy-3,7,11-trimethyldodeca-2,6,10-trienyl)-4-(hydroxymethyl)-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol|arthrobotrisin B

(1R,2S,5R,6S)-1-((1S,2E,4S,6E)-1,4-dihydroxy-3,7,11-trimethyldodeca-2,6,10-trienyl)-4-(hydroxymethyl)-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol|arthrobotrisin B

C22H34O6 (394.2355)


   

(1R,2S,5R,6S)-1-((1S,2E,5R,6E)-1,5-dihydroxy-3,7,11-trimethyldodeca-2,6,10-trienyl)-4-(hydroxymethyl)-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol|arthrobotrisin A

(1R,2S,5R,6S)-1-((1S,2E,5R,6E)-1,5-dihydroxy-3,7,11-trimethyldodeca-2,6,10-trienyl)-4-(hydroxymethyl)-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol|arthrobotrisin A

C22H34O6 (394.2355)


   

viteagnusin|viteagnusin I

viteagnusin|viteagnusin I

C22H34O6 (394.2355)


   

19(10->6)-abeo-ergosta-5,7,9,22-tetraen-3beta-ol|19-norergosta-5,7,9,22-tetraene-3beta-ol

19(10->6)-abeo-ergosta-5,7,9,22-tetraen-3beta-ol|19-norergosta-5,7,9,22-tetraene-3beta-ol

C28H42O (394.3235)


   

2alpha,3alpha,16beta-trihydroxy-20-acetoxy-20(R)-pregnane

2alpha,3alpha,16beta-trihydroxy-20-acetoxy-20(R)-pregnane

C23H38O5 (394.2719)


   

palmadorin S

palmadorin S

C23H38O5 (394.2719)


   

petrosiol E

petrosiol E

C24H42O4 (394.3083)


   

2alpha,3alpha,20-trihydroxy-16beta-acetoxy-20(R)-pregnane

2alpha,3alpha,20-trihydroxy-16beta-acetoxy-20(R)-pregnane

C23H38O5 (394.2719)


   

krempfielin J

krempfielin J

C23H38O5 (394.2719)


   

monocycloalternarene C

monocycloalternarene C

C22H34O6 (394.2355)


   

rel-(4R,4aR,5R,6R,9S,10S,12R,12aR)-3,4,4a,5,6,7,8,9,10,11,12,12a-dodecahydro-9-methoxy-1,6,10-trimethyl-4-(1-methylethyl)-5,12-epoxybenzocyclodecene-6,10-diol 6-acetate|sibogin B

rel-(4R,4aR,5R,6R,9S,10S,12R,12aR)-3,4,4a,5,6,7,8,9,10,11,12,12a-dodecahydro-9-methoxy-1,6,10-trimethyl-4-(1-methylethyl)-5,12-epoxybenzocyclodecene-6,10-diol 6-acetate|sibogin B

C23H38O5 (394.2719)


   

sarcophytonolide Q

sarcophytonolide Q

C22H34O6 (394.2355)


   

chandonanone F

chandonanone F

C22H34O6 (394.2355)


   

palmadorin F

palmadorin F

C23H38O5 (394.2719)


   

(2R,3R,7R,20R)-2,7,20-trihydroxy-3,21-dimethoxy-5-pregnene|heligenin B

(2R,3R,7R,20R)-2,7,20-trihydroxy-3,21-dimethoxy-5-pregnene|heligenin B

C23H38O5 (394.2719)


   

6beta-acetoxy-1alpha,7beta-dihydroxy-8,13-epoxylabd-14-en-11-one|8,13-epoxy-1alpha,6beta,7beta-trihydroxy-labd-14-en-11-one 6-acetate|9-deoxycoleonol B

6beta-acetoxy-1alpha,7beta-dihydroxy-8,13-epoxylabd-14-en-11-one|8,13-epoxy-1alpha,6beta,7beta-trihydroxy-labd-14-en-11-one 6-acetate|9-deoxycoleonol B

C22H34O6 (394.2355)


   

javanicin E

javanicin E

C22H34O6 (394.2355)


   

(15S)-scabronine A

(15S)-scabronine A

C22H34O6 (394.2355)


   

MEGxp0_000928

MEGxp0_000928

C26H34O3 (394.2508)


   

cyclo(L-propyl-L-leucyl-L-alanyl-L-isoleucyl)

cyclo(L-propyl-L-leucyl-L-alanyl-L-isoleucyl)

C20H34N4O4 (394.258)


   

11-acetoxy-4-deacetoxyasbestinin F

11-acetoxy-4-deacetoxyasbestinin F

C22H34O6 (394.2355)


   

ent-18-acetoxy-3beta,7alpha,17-trihydroxy-15beta,16beta-epoxykaurane

ent-18-acetoxy-3beta,7alpha,17-trihydroxy-15beta,16beta-epoxykaurane

C22H34O6 (394.2355)


   

(1alpha,3beta,5beta,6alpha,9beta,10alpha,11beta,13beta)-1,6,11,16-tetrahydroxyabieta-7,15(17)-dien-3-yl acetate|ent-abienervonin A

(1alpha,3beta,5beta,6alpha,9beta,10alpha,11beta,13beta)-1,6,11,16-tetrahydroxyabieta-7,15(17)-dien-3-yl acetate|ent-abienervonin A

C22H34O6 (394.2355)


   

3alpha-epoxyangeloyloxy-4alpha-acetoxy-eudesm-8-one

3alpha-epoxyangeloyloxy-4alpha-acetoxy-eudesm-8-one

C22H34O6 (394.2355)


   

ent-3beta-acetoxy-7alpha,17,18-trihydroxy-15beta,16beta-epoxykaurane

ent-3beta-acetoxy-7alpha,17,18-trihydroxy-15beta,16beta-epoxykaurane

C22H34O6 (394.2355)


   

Isoergosterone

Isoergosterone

C28H42O (394.3235)


   

Enanderianin O|Enanderianin P

Enanderianin O|Enanderianin P

C22H34O6 (394.2355)


   

24-methylenecholesta-5,7,9(11)-trien-3beta-ol

24-methylenecholesta-5,7,9(11)-trien-3beta-ol

C28H42O (394.3235)


   

ergosta-4,22,25-trien-3-one

ergosta-4,22,25-trien-3-one

C28H42O (394.3235)


   

7-Debenzoyloxy-10-deacetyl-brevifoliol

7-Debenzoyloxy-10-deacetyl-brevifoliol

C22H34O6 (394.2355)


   

ent-18-acetoxy-16,17-dihydroxykauran-19-oic acid

ent-18-acetoxy-16,17-dihydroxykauran-19-oic acid

C22H34O6 (394.2355)


   

Peroxyacarnoic acid D

Peroxyacarnoic acid D

C23H38O5 (394.2719)


   

(24S)-24-methylcholesta-4,22E,25-trien-3-one

(24S)-24-methylcholesta-4,22E,25-trien-3-one

C28H42O (394.3235)


   

(Z)-1,20-Diisothiocyanato-1-eicosene

(Z)-1,20-Diisothiocyanato-1-eicosene

C22H38N2S2 (394.2476)


   

asbestinin-21

asbestinin-21

C22H34O6 (394.2355)


   

ergosta-5,7,22,24-tetraen-2beta-ol

ergosta-5,7,22,24-tetraen-2beta-ol

C28H42O (394.3235)


   

12,20-dihydroxy-19-acetoxy-14-methylene geranyl nerol

12,20-dihydroxy-19-acetoxy-14-methylene geranyl nerol

C23H38O5 (394.2719)


   

1-acetoxy-6,7-epoxy-19-hydroxy-12-oxo-smallantha-2Z,14(21)-diene

1-acetoxy-6,7-epoxy-19-hydroxy-12-oxo-smallantha-2Z,14(21)-diene

C23H38O5 (394.2719)


   

1-acetoxy-12-hydroxy-2,3,6,7-bisepoxysmallantha-10E,14(21)-triene

1-acetoxy-12-hydroxy-2,3,6,7-bisepoxysmallantha-10E,14(21)-triene

C23H38O5 (394.2719)


   

6beta-acetoxy-2beta-angeloyloxy-1alpha,10beta,4beta,5alpha-diepoxygermacrane

6beta-acetoxy-2beta-angeloyloxy-1alpha,10beta,4beta,5alpha-diepoxygermacrane

C22H34O6 (394.2355)


   

glyceryl (5R,10R,13R)-7-ketolabda-8-en-15-oate|Glyceryl ester-(ent-13S)-7-Oxo-8-labden-15-oic acid

glyceryl (5R,10R,13R)-7-ketolabda-8-en-15-oate|Glyceryl ester-(ent-13S)-7-Oxo-8-labden-15-oic acid

C23H38O5 (394.2719)


   

javanicin M

javanicin M

C22H34O6 (394.2355)


   

Aspergillus acid D

Aspergillus acid D

C23H38O5 (394.2719)


   

24-methylcholesta-5,7,22,25-tetraen-3beta-ol

24-methylcholesta-5,7,22,25-tetraen-3beta-ol

C28H42O (394.3235)


   

Indicarol acetate

Indicarol acetate

C22H34O6 (394.2355)


   

cytosporic acid

cytosporic acid

C22H34O6 (394.2355)


A monocarboxylic acid that is 3,8-dimethyl-5-oxo-1,2,3,4,4a,8a-hexahydronaphthalene-1-carboxylic acid substituted by a (2R)-hexan-2-yl at position 7, a hydroxy group at position 6 and a 3-hydroxypropanoyl group at position 8. It is a fungal metabolite produced by Cytospora with HIV-1 integrase inhibitory activity.

   

1-acetoxy coleosol|1-Acetoxycoleosol

1-acetoxy coleosol|1-Acetoxycoleosol

C22H34O6 (394.2355)


   

24-norisospiculoic acid A

24-norisospiculoic acid A

C26H34O3 (394.2508)


   

Arachidonoyl-1-thio-Glycerol

5Z,8Z,11Z,14Z-eicosatetraenyl,1-thio glycerol

C23H38O3S (394.2542)


   

(S)-Butaprost (free acid)

(S)-Butaprost (free acid)

C23H38O5 (394.2719)


   

C22H34O6_2-Hydroxy-2,5,5,8a-tetramethyl-5-oxododecahydro-2H-dispiro[furan-3,2-furan-5,1-naphthalen]-4-yl acetate

NCGC00347826-02_C22H34O6_2-Hydroxy-2,5,5,8a-tetramethyl-5-oxododecahydro-2H-dispiro[furan-3,2-furan-5,1-naphthalen]-4-yl acetate

C22H34O6 (394.2355)


   

C22H34O6_(1aR,2S,2aS,5R,5aS,6S,7aS)-2-Acetoxy-5-hydroxy-5-isopropyl-2a,7a-dimethyldecahydroazuleno[5,6-b]oxiren-6-yl (2Z)-2-methyl-2-butenoate

NCGC00384641-01_C22H34O6_(1aR,2S,2aS,5R,5aS,6S,7aS)-2-Acetoxy-5-hydroxy-5-isopropyl-2a,7a-dimethyldecahydroazuleno[5,6-b]oxiren-6-yl (2Z)-2-methyl-2-butenoate

C22H34O6 (394.2355)


   

(3R,5R,7R,9S,10S,12S,13R,14S,17R)-17-((R)-5-hydroxypentan-2-yl)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol

"(3R,5R,7R,9S,10S,12S,13R,14S,17R)-17-((R)-5-hydroxypentan-2-yl)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol"

C24H42O4 (394.3083)


   

(3R,5R,7R,8R,9S,10S,12S,13R,14S,17R)-17-((R)-5-hydroxypentan-2-yl)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol

"(3R,5R,7R,8R,9S,10S,12S,13R,14S,17R)-17-((R)-5-hydroxypentan-2-yl)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol"

C24H42O4 (394.3083)


   

(3R)-3-((3R,5S,7R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)butanoic acid

"(3R)-3-((3R,5S,7R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)butanoic acid"

C23H38O5 (394.2719)


   

(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-17-((R)-5-hydroxypentan-2-yl)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol

"(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-17-((R)-5-hydroxypentan-2-yl)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol"

C24H42O4 (394.3083)


   

gemeprost

gemeprost

C23H38O5 (394.2719)


G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02A - Uterotonics > G02AD - Prostaglandins D012102 - Reproductive Control Agents > D000019 - Abortifacient Agents C78568 - Prostaglandin Analogue

   

(5Z,7E)-(3S)-9,10-seco-5,7,10(19),16-cholestatetraen-23-yne-3,25-diol

25-hydroxy-16,17,23,23,24,24-hexadehydrovitamin D3 / 25-hydroxy-16,17,23,23,24,24-hexadehydrocholecalciferol

C27H38O2 (394.2872)


   

5β-Cholane-3α,7α,12α,24-tetrol

5β-Cholane-3α,7α,12α,24-tetrol

C24H42O4 (394.3083)


   

5β-Cholane-3α,7α,23,24-tetrol

5β-Cholane-3α,7α,23,24-tetrol

C24H42O4 (394.3083)


   

8-sio Prostaglandin E2 isopropyl ester

8-sio Prostaglandin E2 isopropyl ester

C23H38O5 (394.2719)


   

2-(14,15-Epoxyeicosatrienoyl) Glycerol

2-(14,15-Epoxyeicosatrienoyl) Glycerol

C23H38O5 (394.2719)


   

(R)-Butaprost (free acid)

9-oxo-11α,16R-dihydroxy-17-cyclobutyl-prost-13E-en-1-oic acid

C23H38O5 (394.2719)


   

Prostaglandin E2 isopropyl ester

9-oxo-11α,15S-dihydroxy-prosta-5Z,13E-dien-1-oic acid, isopropyl ester

C23H38O5 (394.2719)


   

Butaprost (free acid)

9-oxo-11α,16S-dihydroxy-17-cyclobutyl-prost-13E-en-1-oic acid

C23H38O5 (394.2719)


   

LPA(P-16:0e/0:0)

1-(1Z-hexadecenyl)-sn-glycero-3-phosphate;LysoPA(dm16:0e)

C19H39O6P (394.2484)


   

15-HETE-G

2-(15S-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoyl)-sn-glycerol

C23H38O5 (394.2719)


   

12-HETE-G

2-(12S-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoyl)-sn-glycerol

C23H38O5 (394.2719)


   

PA(P-16:0/0:0)

1-(1Z-hexadecenyl)-glycero-3-phosphate

C19H39O6P (394.2484)


   

11-HETE-g

1,3-dihydroxypropan-2-yl (5Z,8Z,11S,12E,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoate

C23H38O5 (394.2719)


   

(3b,6b,8b,12a)-8,12-Epoxy-7(11)-eremophilene-6-angeloyloxy-8,12-dimethoxy-3-ol

6-hydroxy-2,9a-dimethoxy-3,4a,5-trimethyl-2H,4H,4aH,5H,6H,7H,8H,8aH,9H,9aH-naphtho[2,3-b]furan-4-yl (2E)-2-methylbut-2-enoate

C22H34O6 (394.2355)


   

7,8-Dehydro-b-micropteroxanthin

4-[(3E,5E,7E,9E,11E)-15-hydroxy-3,7,12-trimethylpentadeca-3,5,7,9,11-pentaen-1-yn-1-yl]-3,5,5-trimethylcyclohex-3-en-1-ol

C27H38O2 (394.2872)


   

3'-Methoxy-[6]-Gingerdiol 3,5-diacetate

3-(acetyloxy)-1-(3,4-dimethoxyphenyl)decan-5-yl acetate

C22H34O6 (394.2355)


   

(3beta,22E,24R)-Ergosta-4,6,8(14),22-tetraen-3-ol

14-[(3E)-5,6-dimethylhept-3-en-2-yl]-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-6,8,10-trien-5-ol

C28H42O (394.3235)


   

Latanoprost (free acid)-d4

Latanoprost (free acid)-d4

C23H30D4O5 (394.2657)


   

FA 22:5;O4

(S)-4-hydroxy-4-((2S,4S,5S)-4-hydroxy-5-((S,1E,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)tetrahydrofuran-2-yl)butanoic acid

C22H34O6 (394.2355)


   

MG 20:4;O

1-(2S-methoxy-12-methyloctadeca-7Z,17-dien-5-ynoyl)-sn-glycerol

C23H38O5 (394.2719)


   

LPA O-16:1

1-(1Z-hexadecenyl)-glycero-3-phosphate

C19H39O6P (394.2484)


   

1-palmitylglycerone 3-phosphate

1-hexadecyl-glycerone 3-phosphate

C19H39O6P (394.2484)


A 1-alkylglycerone 3-phosphate in which the alkyl group is specified as palmityl (hexadecyl).

   

ST 28:4;O

(22E)-24-methylcholesta-5,7,22,24(24(1))-tetraen-3beta-ol

C28H42O (394.3235)


   

25-hydroxy-16,17,23,23,24,24-hexadehydrovitamin D3

(5Z,7E)-(3S)-9,10-seco-5,7,10(19),16-cholestatetraen-23-yne-3,25-diol

C27H38O2 (394.2872)


   

ST 24:0;O4

5beta-Cholane-3alpha,7alpha,12alpha,24-tetrol

C24H42O4 (394.3083)


   

Norcholic acid

24-nor-3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-23-oic acid

C23H38O5 (394.2719)


D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids Norcholic acid is a normal minorbile C23 bile acid having four side chain and exsits in human urine and meconium. Norcholic acid can become prominent under certain pathological conditions. Norcholic acid is efficiently absorbed from intestine and quickly excreted into the bile but not into urine[1].

   

ST 23:1;O5

24-nor-3alpha,7alpha,16alpha-trihydroxy-5beta-cholan-23-oic acid

C23H38O5 (394.2719)


   

2-hydroxy-5-methoxy-3-(2R-acetoxy-tridecyl)-1,4-benzoquinone

2-hydroxy-5-methoxy-3-(2R-acetoxy-tridecyl)-1,4-benzoquinone

C22H34O6 (394.2355)


   

(1-PYRROLIDIN-3-YL-PIPERIDIN-4-YL)-CARBAMICACIDTERT-BUTYLESTER

(1-PYRROLIDIN-3-YL-PIPERIDIN-4-YL)-CARBAMICACIDTERT-BUTYLESTER

C24H42O4 (394.3083)


   

2-(2-hydroxyethyliminomethylideneamino)ethyl (Z)-octadec-9-enoate

2-(2-hydroxyethyliminomethylideneamino)ethyl (Z)-octadec-9-enoate

C23H42N2O3 (394.3195)


   

1-DEOXYFORSKOLIN

1-DEOXYFORSKOLIN

C22H34O6 (394.2355)


   

Hexadecyl 3,4,5-trihydroxybenzoate

Hexadecyl 3,4,5-trihydroxybenzoate

C23H38O5 (394.2719)


   

[4-(hydroxymethyl)-2,5-dioctoxyphenyl]methanol

[4-(hydroxymethyl)-2,5-dioctoxyphenyl]methanol

C24H42O4 (394.3083)


   

Tributyl(octyl)phosphonium bromide

Tributyl(octyl)phosphonium bromide

C20H44BrP (394.2364)


   

Dioctyl phthalate-d4

Dioctyl phthalate-d4

C24H34D4O4 (394.3021)


   

4-heptylphenyl 4-heptylbenzoate

4-heptylphenyl 4-heptylbenzoate

C27H38O2 (394.2872)


   

Dioctan-2-yl phthalate

Dioctan-2-yl phthalate

C24H42O4 (394.3083)


   

1,2,3,6-TETRAHYDROPHTHALIC ACID DI(2-ETHYLHEXYL) ESTER

1,2,3,6-TETRAHYDROPHTHALIC ACID DI(2-ETHYLHEXYL) ESTER

C24H42O4 (394.3083)


   

Boc-d-pra-oh dcha

Boc-d-pra-oh dcha

C22H38N2O4 (394.2831)


   

1-HEXADECYL-3-METHYLIMIDAZOLIUM TETRAFLUOROBORATE

1-HEXADECYL-3-METHYLIMIDAZOLIUM TETRAFLUOROBORATE

C20H39BF4N2 (394.3142)


   

2-(1,1-dimethylethyl)-6-[[3-(1,1-dimethylethyl)-2-hydroxy-5-methylphenyl]methyl]-4-methylphenyl acrylate

2-(1,1-dimethylethyl)-6-[[3-(1,1-dimethylethyl)-2-hydroxy-5-methylphenyl]methyl]-4-methylphenyl acrylate

C26H34O3 (394.2508)


   

1-[4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl]-3-propan-2-ylimidazolidin-2-one

1-[4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl]-3-propan-2-ylimidazolidin-2-one

C23H30N4O2 (394.2369)


   

sodium 1-(carboxymethyl)-4,5-dihydro-1(or 3)-(2-hydroxyethyl)-2-tridecyl-1H-imidazolium hydroxide

sodium 1-(carboxymethyl)-4,5-dihydro-1(or 3)-(2-hydroxyethyl)-2-tridecyl-1H-imidazolium hydroxide

C20H39N2NaO4 (394.2807)


   

1,2,3-Trifluoro-5-{4-[2-(4-pentylcyclohexyl)ethyl]cyclohexyl}benz ene

1,2,3-Trifluoro-5-{4-[2-(4-pentylcyclohexyl)ethyl]cyclohexyl}benz ene

C25H37F3 (394.2847)


   

bis(2-ethylhexyl) 3,4,5,6-tetradeuteriobenzene-1,2-dicarboxylate

bis(2-ethylhexyl) 3,4,5,6-tetradeuteriobenzene-1,2-dicarboxylate

C24H34D4O4 (394.3021)


   

(1S)-(-)-TRANS-PINANE

(1S)-(-)-TRANS-PINANE

C24H42O4 (394.3083)


   

DI-N-OCTYL 4-CYCLOHEXENE-1,2-DICARBOXYLATE

DI-N-OCTYL 4-CYCLOHEXENE-1,2-DICARBOXYLATE

C24H42O4 (394.3083)


   

3-(Dodecylthio)-1-(2,6,6-trimethyl-3-cyclohexen-1-yl)-1-butanone

3-(Dodecylthio)-1-(2,6,6-trimethyl-3-cyclohexen-1-yl)-1-butanone

C25H46OS (394.3269)


   

1-Ethoxy-2,3-difluoro-4-[[(trans,trans)-4-propyl[1,1-bicyclohexyl]-4-yl]methoxy]benzene

1-Ethoxy-2,3-difluoro-4-[[(trans,trans)-4-propyl[1,1-bicyclohexyl]-4-yl]methoxy]benzene

C24H36F2O2 (394.2683)


   

(4-ethoxyphenyl) 4-(4-pentylcyclohexyl)benzoate

(4-ethoxyphenyl) 4-(4-pentylcyclohexyl)benzoate

C26H34O3 (394.2508)


   

RHC-80267

1,6-Bis(cyclohexyloximinocarbonyl)hexane

C20H34N4O4 (394.258)


D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors

   

hexaethylene glycol monooctyl ether

hexaethylene glycol monooctyl ether

C20H42O7 (394.293)


   

1,3-BIS((DI-TERT-BUTYLPHOSPHINO)METHYL)BENZENE

1,3-BIS((DI-TERT-BUTYLPHOSPHINO)METHYL)BENZENE

C24H44P2 (394.2918)


   

1,2-Bis(di-tert-butyl phosphinomethyl)benzene

1,2-Bis(di-tert-butyl phosphinomethyl)benzene

C24H44P2 (394.2918)


   

N-[4-(2,6-dimethylpiperidin-1-yl)butyl]-2-phenoxy-2-phenylacetamide

N-[4-(2,6-dimethylpiperidin-1-yl)butyl]-2-phenoxy-2-phenylacetamide

C25H34N2O2 (394.262)


   

24-Methylenecholesta-1,4-dien-3-one

24-Methylenecholesta-1,4-dien-3-one

C28H42O (394.3235)


An ergostanoid that is ergosta-1,4,24(28)-triene substituted by an oxo group at position 3. It is isolated from Hainan soft coral Dendronephthya studeri.

   

3-(Hexadecyloxy)-2-oxopropyl dihydrogen phosphate

3-(Hexadecyloxy)-2-oxopropyl dihydrogen phosphate

C19H39O6P (394.2484)


   

1,3-Cyclohexanediol, 4-Methylene-5-[(2e)-[(1s,3as,7as)-Octahydro-1-(5-Hydroxy-5-Methyl-1,3-Hexadiynyl)-7a-Methyl-4h-Inden-4-Ylidene]ethylidene]-, (1r,3s,5z)

1,3-Cyclohexanediol, 4-Methylene-5-[(2e)-[(1s,3as,7as)-Octahydro-1-(5-Hydroxy-5-Methyl-1,3-Hexadiynyl)-7a-Methyl-4h-Inden-4-Ylidene]ethylidene]-, (1r,3s,5z)

C26H34O3 (394.2508)


   

3-[(3R,10S,12S,13R,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]butanoic acid

3-[(3R,10S,12S,13R,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]butanoic acid

C23H38O5 (394.2719)


   

2-glyceryl 11,12-epoxy-(5Z,8Z,14Z)-icosatrienoate

2-glyceryl 11,12-epoxy-(5Z,8Z,14Z)-icosatrienoate

C23H38O5 (394.2719)


A 2-monoglyceride obtained by formal condensation of the carboxy group of 11,12-epoxy-(5Z,8Z,14Z)-icosatrienoic acid with the 2-hydroxy group of glycerol.

   

methyl (E)-7-[3-hydroxy-2-[(E)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxocyclopentyl]hept-2-enoate

methyl (E)-7-[3-hydroxy-2-[(E)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxocyclopentyl]hept-2-enoate

C23H38O5 (394.2719)


   

17-[(E)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,12,14,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-3-ol

17-[(E)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,12,14,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-3-ol

C28H42O (394.3235)


   

MG(20:3(5Z,8Z,11Z)-O(14R,15S)/0:0/0:0)

MG(20:3(5Z,8Z,11Z)-O(14R,15S)/0:0/0:0)

C23H38O5 (394.2719)


   

MG(20:3(5Z,8Z,14Z)-O(11S,12R)/0:0/0:0)

MG(20:3(5Z,8Z,14Z)-O(11S,12R)/0:0/0:0)

C23H38O5 (394.2719)


   

MG(20:3(5Z,11Z,14Z)-O(8,9)/0:0/0:0)

MG(20:3(5Z,11Z,14Z)-O(8,9)/0:0/0:0)

C23H38O5 (394.2719)


   

MG(20:3(8Z,11Z,14Z)-O(5,6)/0:0/0:0)

MG(20:3(8Z,11Z,14Z)-O(5,6)/0:0/0:0)

C23H38O5 (394.2719)


   

MG(20:4(5Z,8Z,11Z,14Z)-OH(20)/0:0/0:0)

MG(20:4(5Z,8Z,11Z,14Z)-OH(20)/0:0/0:0)

C23H38O5 (394.2719)


   

MG(20:4(6E,8Z,11Z,14Z)-OH(5S)/0:0/0:0)

MG(20:4(6E,8Z,11Z,14Z)-OH(5S)/0:0/0:0)

C23H38O5 (394.2719)


   

MG(20:4(5Z,8Z,11Z,14Z)-OH(19S)/0:0/0:0)

MG(20:4(5Z,8Z,11Z,14Z)-OH(19S)/0:0/0:0)

C23H38O5 (394.2719)


   

MG(20:4(5Z,8Z,11Z,14Z)-OH(18R)/0:0/0:0)

MG(20:4(5Z,8Z,11Z,14Z)-OH(18R)/0:0/0:0)

C23H38O5 (394.2719)


   

MG(20:4(5Z,8Z,11Z,14Z)-OH(17)/0:0/0:0)

MG(20:4(5Z,8Z,11Z,14Z)-OH(17)/0:0/0:0)

C23H38O5 (394.2719)


   

MG(20:4(5Z,8Z,11Z,14Z)-OH(16R)/0:0/0:0)

MG(20:4(5Z,8Z,11Z,14Z)-OH(16R)/0:0/0:0)

C23H38O5 (394.2719)


   

MG(20:4(5Z,8Z,11Z,13E)-OH(15S)/0:0/0:0)

MG(20:4(5Z,8Z,11Z,13E)-OH(15S)/0:0/0:0)

C23H38O5 (394.2719)


   

MG(20:4(5Z,8Z,10E,14Z)-OH(12S)/0:0/0:0)

MG(20:4(5Z,8Z,10E,14Z)-OH(12S)/0:0/0:0)

C23H38O5 (394.2719)


   

MG(20:4(5E,8Z,12Z,14Z)-OH(11R)/0:0/0:0)

MG(20:4(5E,8Z,12Z,14Z)-OH(11R)/0:0/0:0)

C23H38O5 (394.2719)


   

MG(20:4(5Z,7E,11Z,14Z)-OH(9)/0:0/0:0)

MG(20:4(5Z,7E,11Z,14Z)-OH(9)/0:0/0:0)

C23H38O5 (394.2719)


   

MG(0:0/20:3(5Z,11Z,14Z)-O(8,9)/0:0)

MG(0:0/20:3(5Z,11Z,14Z)-O(8,9)/0:0)

C23H38O5 (394.2719)


   

MG(0:0/20:3(8Z,11Z,14Z)-O(5,6)/0:0)

MG(0:0/20:3(8Z,11Z,14Z)-O(5,6)/0:0)

C23H38O5 (394.2719)


   

MG(0:0/20:4(5Z,8Z,11Z,14Z)-OH(20)/0:0)

MG(0:0/20:4(5Z,8Z,11Z,14Z)-OH(20)/0:0)

C23H38O5 (394.2719)


   

MG(0:0/20:4(6E,8Z,11Z,14Z)-OH(5S)/0:0)

MG(0:0/20:4(6E,8Z,11Z,14Z)-OH(5S)/0:0)

C23H38O5 (394.2719)


   

MG(0:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)/0:0)

MG(0:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)/0:0)

C23H38O5 (394.2719)


   

MG(0:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)/0:0)

MG(0:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)/0:0)

C23H38O5 (394.2719)


   

MG(0:0/20:4(5Z,8Z,11Z,14Z)-OH(17)/0:0)

MG(0:0/20:4(5Z,8Z,11Z,14Z)-OH(17)/0:0)

C23H38O5 (394.2719)


   

MG(0:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)/0:0)

MG(0:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)/0:0)

C23H38O5 (394.2719)


   

MG(0:0/20:4(5E,8Z,12Z,14Z)-OH(11R)/0:0)

MG(0:0/20:4(5E,8Z,12Z,14Z)-OH(11R)/0:0)

C23H38O5 (394.2719)


   

MG(0:0/20:4(5Z,7E,11Z,14Z)-OH(9)/0:0)

MG(0:0/20:4(5Z,7E,11Z,14Z)-OH(9)/0:0)

C23H38O5 (394.2719)


   

[3-carboxy-2-[(5E,8E,11E)-hexadeca-5,8,11-trienoyl]oxypropyl]-trimethylazanium

[3-carboxy-2-[(5E,8E,11E)-hexadeca-5,8,11-trienoyl]oxypropyl]-trimethylazanium

C23H40NO4+ (394.2957)


   

[3-carboxy-2-[(7E,10E,13E)-hexadeca-7,10,13-trienoyl]oxypropyl]-trimethylazanium

[3-carboxy-2-[(7E,10E,13E)-hexadeca-7,10,13-trienoyl]oxypropyl]-trimethylazanium

C23H40NO4+ (394.2957)


   

[3-carboxy-2-[(6E,9E,12E)-hexadeca-6,9,12-trienoyl]oxypropyl]-trimethylazanium

[3-carboxy-2-[(6E,9E,12E)-hexadeca-6,9,12-trienoyl]oxypropyl]-trimethylazanium

C23H40NO4+ (394.2957)


   

[3-carboxy-2-[(4E,7E,10E)-hexadeca-4,7,10-trienoyl]oxypropyl]-trimethylazanium

[3-carboxy-2-[(4E,7E,10E)-hexadeca-4,7,10-trienoyl]oxypropyl]-trimethylazanium

C23H40NO4+ (394.2957)


   

[3-carboxy-2-[(7E,11E,14E)-hexadeca-7,11,14-trienoyl]oxypropyl]-trimethylazanium

[3-carboxy-2-[(7E,11E,14E)-hexadeca-7,11,14-trienoyl]oxypropyl]-trimethylazanium

C23H40NO4+ (394.2957)


   

[3-carboxy-2-[(4E,7E,13E)-hexadeca-4,7,13-trienoyl]oxypropyl]-trimethylazanium

[3-carboxy-2-[(4E,7E,13E)-hexadeca-4,7,13-trienoyl]oxypropyl]-trimethylazanium

C23H40NO4+ (394.2957)


   

[3-carboxy-2-[(6E,10E,14E)-hexadeca-6,10,14-trienoyl]oxypropyl]-trimethylazanium

[3-carboxy-2-[(6E,10E,14E)-hexadeca-6,10,14-trienoyl]oxypropyl]-trimethylazanium

C23H40NO4+ (394.2957)


   

Stanolone benzoate

Androstanolone 17-benzoate

C26H34O3 (394.2508)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones

   

Propenediester

Propenediester

C24H42O4 (394.3083)


   

arthrobotrisin C

arthrobotrisin C

C22H34O6 (394.2355)


A natural product found in Arthrobotrys oligospora.

   

arthrobotrisin B

arthrobotrisin B

C22H34O6 (394.2355)


A natural product found in Arthrobotrys oligospora.

   

Viteagnusin I

Viteagnusin I

C22H34O6 (394.2355)


A labdane diterpenoid that is isolated from the fruits of Vitex agnus-castus.

   

Arthrobotrisin A

Arthrobotrisin A

C22H34O6 (394.2355)


A natural product found in Arthrobotrys oligospora.

   

1-Hexadecyl-sn-glycero-3-phosphate(2-)

1-Hexadecyl-sn-glycero-3-phosphate(2-)

C19H39O6P-2 (394.2484)


   

(22E,24S)-24-methylcholesta-5,7,14,22-tetraen-3beta-ol

(22E,24S)-24-methylcholesta-5,7,14,22-tetraen-3beta-ol

C28H42O (394.3235)


A 3beta-sterol that is ergosterol having an additional double bond at position 14.

   

1-O-palmityl-2-desoxy-2-amino-sn-glycero-3-phosphate(1-)

1-O-palmityl-2-desoxy-2-amino-sn-glycero-3-phosphate(1-)

C19H41NO5P- (394.2722)


   
   

(2S)-4-methyl-2-{[(9Z)-octadec-9-enoyl]amino}pentanoate

(2S)-4-methyl-2-{[(9Z)-octadec-9-enoyl]amino}pentanoate

C24H44NO3- (394.3321)


   

(2S,3S)-3-methyl-2-{[(9Z)-octadec-9-enoyl]amino}pentanoate

(2S,3S)-3-methyl-2-{[(9Z)-octadec-9-enoyl]amino}pentanoate

C24H44NO3- (394.3321)


   

(8E,10Z,13Z,15E,19Z)-7,17-bis(hydroperoxy)docosa-8,10,13,15,19-pentaenoic acid

(8E,10Z,13Z,15E,19Z)-7,17-bis(hydroperoxy)docosa-8,10,13,15,19-pentaenoic acid

C22H34O6 (394.2355)


   

(4Z,7Z,11Z,13Z,15E,17S)-10,17-bis(hydroperoxy)docosa-4,7,11,13,15-pentaenoic acid

(4Z,7Z,11Z,13Z,15E,17S)-10,17-bis(hydroperoxy)docosa-4,7,11,13,15-pentaenoic acid

C22H34O6 (394.2355)


   

3-cyclopentyl-1-[[(2S,3R,4S)-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-1-methylurea

3-cyclopentyl-1-[[(2S,3R,4S)-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-1-methylurea

C23H30N4O2 (394.2369)


   

[(3aR,4S,9bS)-8-(1-cyclohexenyl)-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-cyclopentylmethanone

[(3aR,4S,9bS)-8-(1-cyclohexenyl)-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-cyclopentylmethanone

C25H34N2O2 (394.262)


   

[(3aS,4R,9bR)-8-(1-cyclohexenyl)-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-cyclopentylmethanone

[(3aS,4R,9bR)-8-(1-cyclohexenyl)-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-cyclopentylmethanone

C25H34N2O2 (394.262)


   

[(2S,3R)-6-(4-oxanylmethyl)-3-phenyl-1-(5-pyrimidinylmethyl)-1,6-diazaspiro[3.3]heptan-2-yl]methanol

[(2S,3R)-6-(4-oxanylmethyl)-3-phenyl-1-(5-pyrimidinylmethyl)-1,6-diazaspiro[3.3]heptan-2-yl]methanol

C23H30N4O2 (394.2369)


   

(7Z,11Z,13Z,15E,19Z)-10,17-bis(hydroperoxy)docosa-7,11,13,15,19-pentaenoic acid

(7Z,11Z,13Z,15E,19Z)-10,17-bis(hydroperoxy)docosa-7,11,13,15,19-pentaenoic acid

C22H34O6 (394.2355)


   

N,N-bis(diphenylmethyl)ethane-1,2-bis(aminium)

N,N-bis(diphenylmethyl)ethane-1,2-bis(aminium)

C28H30N2+2 (394.2409)


   

Fahfa 19:2/5:0

Fahfa 19:2/5:0

C24H42O4 (394.3083)


   

[1-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]-3-hydroxypropan-2-yl] pentanoate

[1-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]-3-hydroxypropan-2-yl] pentanoate

C24H42O4 (394.3083)


   

[1-hydroxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propan-2-yl] propanoate

[1-hydroxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propan-2-yl] propanoate

C24H42O4 (394.3083)


   

(1S,2S,3E,7S,8R,11S,12Z)-7-Acetoxy-2,17-dihydroxy-8,11-epidioxycembra-3,12,15-triene

(1S,2S,3E,7S,8R,11S,12Z)-7-Acetoxy-2,17-dihydroxy-8,11-epidioxycembra-3,12,15-triene

C22H34O6 (394.2355)


   

[3-carboxy-2-[(9Z,11E,13E)-hexadeca-9,11,13-trienoyl]oxypropyl]-trimethylazanium

[3-carboxy-2-[(9Z,11E,13E)-hexadeca-9,11,13-trienoyl]oxypropyl]-trimethylazanium

C23H40NO4+ (394.2957)


   

Fahfa 3:0/21:2

Fahfa 3:0/21:2

C24H42O4 (394.3083)


   

Fahfa 7:0/17:2

Fahfa 7:0/17:2

C24H42O4 (394.3083)


   

Fahfa 17:2/7:0

Fahfa 17:2/7:0

C24H42O4 (394.3083)


   

Fahfa 16:2/8:0

Fahfa 16:2/8:0

C24H42O4 (394.3083)


   

Fahfa 18:2/6:0

Fahfa 18:2/6:0

C24H42O4 (394.3083)


   

Fahfa 6:0/18:2

Fahfa 6:0/18:2

C24H42O4 (394.3083)


   

Fahfa 2:0/22:2

Fahfa 2:0/22:2

C24H42O4 (394.3083)


   

Fahfa 4:0/20:2

Fahfa 4:0/20:2

C24H42O4 (394.3083)


   

Fahfa 8:0/16:2

Fahfa 8:0/16:2

C24H42O4 (394.3083)


   

Fahfa 5:0/19:2

Fahfa 5:0/19:2

C24H42O4 (394.3083)


   

Fahfa 20:2/4:0

Fahfa 20:2/4:0

C24H42O4 (394.3083)


   

Fahfa 21:2/3:0

Fahfa 21:2/3:0

C24H42O4 (394.3083)


   

(4aS,4aalpha)-Decahydro-2,5beta-dimethyl-8abeta-methoxymethoxymethyl-5alpha-(4-methyl-3-pentenyl)-1-oxonaphthalene-2xi-carboxylic acid methyl ester

(4aS,4aalpha)-Decahydro-2,5beta-dimethyl-8abeta-methoxymethoxymethyl-5alpha-(4-methyl-3-pentenyl)-1-oxonaphthalene-2xi-carboxylic acid methyl ester

C23H38O5 (394.2719)


   

(1-butanoyloxy-3-hydroxypropan-2-yl) (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

(1-butanoyloxy-3-hydroxypropan-2-yl) (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C23H38O5 (394.2719)


   

2-[(13Z,16Z)-docosa-13,16-dienoyl]oxyacetic acid

2-[(13Z,16Z)-docosa-13,16-dienoyl]oxyacetic acid

C24H42O4 (394.3083)


   

(1-acetyloxy-3-hydroxypropan-2-yl) (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

(1-acetyloxy-3-hydroxypropan-2-yl) (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C23H38O5 (394.2719)


   

1-(1Z-hexadecenyl)-glycero-3-phosphate

1-(1Z-hexadecenyl)-glycero-3-phosphate

C19H39O6P (394.2484)


   

11-Hydroxyeicosatetraenoate glyceryl ester

11-Hydroxyeicosatetraenoate glyceryl ester

C23H38O5 (394.2719)


   

7,8-Dehydro-beta-micropteroxanthin

7,8-Dehydro-beta-micropteroxanthin

C27H38O2 (394.2872)


   

Dehydroergosterol

Dehydroergosterol

C28H42O (394.3235)


A phytosterol consiting of ergostane having double bonds at the 5,6-, 7,8- 9,11- and 22,23-positions as well as a 3beta-hydroxy group.

   

5beta-Cholane-3alpha,7alpha,12alpha,24-tetrol

5beta-Cholane-3alpha,7alpha,12alpha,24-tetrol

C24H42O4 (394.3083)


   

Norhyocholic acid

Norhyocholic acid

C23H38O5 (394.2719)


   

Nor-beta-muricholic acid

Nor-beta-muricholic acid

C23H38O5 (394.2719)


   

Nor-alpha-muricholic acid

Nor-alpha-muricholic acid

C23H38O5 (394.2719)


   

5beta-Cholane-3alpha,7alpha,23,24-tetrol

5beta-Cholane-3alpha,7alpha,23,24-tetrol

C24H42O4 (394.3083)


   

(8E,10Z,13Z,15E,19Z)-7,17-bis(hydroperoxy)docosapentaenoic acid

(8E,10Z,13Z,15E,19Z)-7,17-bis(hydroperoxy)docosapentaenoic acid

C22H34O6 (394.2355)


A hydroperoxydocosapentaenoic acid that is (8E,10Z,13Z,15E,19Z)-docosapentaenooic acid carrying two hydroperoxy substituents at positions 7 and 17. An intermediate of specialised proresolving mediators.

   

(4Z,7Z,11Z,13Z,15E,17S)-10,17-bis(hydroperoxy)docosapentaenoic acid

(4Z,7Z,11Z,13Z,15E,17S)-10,17-bis(hydroperoxy)docosapentaenoic acid

C22H34O6 (394.2355)


A hydroperoxydocosapentaenoic acid that is (4Z,7Z,11Z,13Z,15E)-docosapentaenoic acid carrying two hydroperoxy substituents at positions 10 and 17.

   

Noravicholic acid

Noravicholic acid

C23H38O5 (394.2719)


   

delta18-13-NeuroF

delta18-13-NeuroF

C22H34O6 (394.2355)


   

Nor-omega-muricholic acid

24-nor-3alpha,6alpha,7beta-trihydroxy-5beta-cholan-23-oic acid

C23H38O5 (394.2719)


   

(5R,8R,11R)-d9-4-NeuroF[4S,7R]

(5R,8R,11R)-d9-4-NeuroF[4S,7R]

C22H34O6 (394.2355)


   

(7R,10S,14R)-d12-8-NeuroF[8S,11S]

(7R,10S,14R)-d12-8-NeuroF[8S,11S]

C22H34O6 (394.2355)


   

(10S,13S,17R)-d15-11-NeuroF[11R,14S]

(10S,13S,17R)-d15-11-NeuroF[11R,14S]

C22H34O6 (394.2355)


   

(1Z)-3-Acetoxy-1-propen-1-yl 5-methyleneoctadecanoate

(1Z)-3-Acetoxy-1-propen-1-yl 5-methyleneoctadecanoate

C24H42O4 (394.3083)


A natural product found in Oscillatoria species.

   

2-glyceryl 14,15-epoxy-(5Z,8Z,11Z)-icosatrienoate

2-glyceryl 14,15-epoxy-(5Z,8Z,11Z)-icosatrienoate

C23H38O5 (394.2719)


A 2-monoglyceride obtained by formal condensation of the carboxy group of 14,15-EET with the 2-hydroxy group of glycerol.

   

1-Hexadecyl-sn-glycero-3-phosphate(2-)

1-Hexadecyl-sn-glycero-3-phosphate(2-)

C19H39O6P (394.2484)


A 1-alkyl-sn-glycerol 3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of 1-hexadecyl-sn-glycero-3-phosphate; major species at pH 7.3.

   

DG(21:3)

DG(10:1(1)_11:2)

C24H42O4 (394.3083)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

DG(20:3)

DG(10:0_10:3)

C23H38O5 (394.2719)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

NA-Asn 18:2(9E,12E)

NA-Asn 18:2(9E,12E)

C22H38N2O4 (394.2831)


   

NA-Asn 18:2(9Z,12Z)

NA-Asn 18:2(9Z,12Z)

C22H38N2O4 (394.2831)


   

NA-Gln 17:2(9Z,12Z)

NA-Gln 17:2(9Z,12Z)

C22H38N2O4 (394.2831)


   

NA-Lys 17:2(9Z,12Z)

NA-Lys 17:2(9Z,12Z)

C23H42N2O3 (394.3195)


   

NA-Orn 18:2(9E,12E)

NA-Orn 18:2(9E,12E)

C23H42N2O3 (394.3195)


   

NA-Orn 18:2(9Z,12Z)

NA-Orn 18:2(9Z,12Z)

C23H42N2O3 (394.3195)


   

FAHFA 10:0/O-14:2

FAHFA 10:0/O-14:2

C24H42O4 (394.3083)


   

FAHFA 10:1/O-14:1

FAHFA 10:1/O-14:1

C24H42O4 (394.3083)


   

FAHFA 10:2/O-14:0

FAHFA 10:2/O-14:0

C24H42O4 (394.3083)


   

FAHFA 11:0/O-13:2

FAHFA 11:0/O-13:2

C24H42O4 (394.3083)


   

FAHFA 11:1/O-13:1

FAHFA 11:1/O-13:1

C24H42O4 (394.3083)


   

FAHFA 11:2/O-13:0

FAHFA 11:2/O-13:0

C24H42O4 (394.3083)


   

FAHFA 12:0/O-12:2

FAHFA 12:0/O-12:2

C24H42O4 (394.3083)


   

FAHFA 12:1/O-12:1

FAHFA 12:1/O-12:1

C24H42O4 (394.3083)


   

FAHFA 12:2/O-12:0

FAHFA 12:2/O-12:0

C24H42O4 (394.3083)


   

FAHFA 13:0/O-11:2

FAHFA 13:0/O-11:2

C24H42O4 (394.3083)


   

FAHFA 13:1/O-11:1

FAHFA 13:1/O-11:1

C24H42O4 (394.3083)


   

FAHFA 13:2/O-11:0

FAHFA 13:2/O-11:0

C24H42O4 (394.3083)


   

FAHFA 14:0/O-10:2

FAHFA 14:0/O-10:2

C24H42O4 (394.3083)


   

FAHFA 14:1/O-10:1

FAHFA 14:1/O-10:1

C24H42O4 (394.3083)


   

FAHFA 14:2/O-10:0

FAHFA 14:2/O-10:0

C24H42O4 (394.3083)


   

FAHFA 15:0/O-9:2

FAHFA 15:0/O-9:2

C24H42O4 (394.3083)


   

FAHFA 15:1/O-9:1

FAHFA 15:1/O-9:1

C24H42O4 (394.3083)


   

FAHFA 15:2/O-9:0

FAHFA 15:2/O-9:0

C24H42O4 (394.3083)


   

FAHFA 16:0/O-8:2

FAHFA 16:0/O-8:2

C24H42O4 (394.3083)


   

FAHFA 16:1/O-8:1

FAHFA 16:1/O-8:1

C24H42O4 (394.3083)


   

FAHFA 16:2/O-8:0

FAHFA 16:2/O-8:0

C24H42O4 (394.3083)


   

FAHFA 18:2(9Z,12Z)/3O-6:0

FAHFA 18:2(9Z,12Z)/3O-6:0

C24H42O4 (394.3083)


   

FAHFA 24:2;O

FAHFA 24:2;O

C24H42O4 (394.3083)


   

FAHFA 8:0/O-16:2

FAHFA 8:0/O-16:2

C24H42O4 (394.3083)


   

FAHFA 8:1/O-16:1

FAHFA 8:1/O-16:1

C24H42O4 (394.3083)


   

FAHFA 8:2/O-16:0

FAHFA 8:2/O-16:0

C24H42O4 (394.3083)


   

FAHFA 9:0/O-15:2

FAHFA 9:0/O-15:2

C24H42O4 (394.3083)


   

FAHFA 9:1/O-15:1

FAHFA 9:1/O-15:1

C24H42O4 (394.3083)


   

FAHFA 9:2/O-15:0

FAHFA 9:2/O-15:0

C24H42O4 (394.3083)


   
   

LPA P-16:0 or LPA O-16:1

LPA P-16:0 or LPA O-16:1

C19H39O6P (394.2484)


   
   
   
   

1-hydroxy-1-(1-hydroxyethyl)-7,7-dimethoxy-9a,11a-dimethyl-dodecahydrocyclopenta[a]phenanthren-2-one

1-hydroxy-1-(1-hydroxyethyl)-7,7-dimethoxy-9a,11a-dimethyl-dodecahydrocyclopenta[a]phenanthren-2-one

C23H38O5 (394.2719)


   

(1s,2r,4s,6s,7r,8s,11s)-7-(acetyloxy)-8-isopropyl-4,11-dimethyl-5,12-dioxatricyclo[9.1.0.0⁴,⁶]dodecan-2-yl (2z)-2-methylbut-2-enoate

(1s,2r,4s,6s,7r,8s,11s)-7-(acetyloxy)-8-isopropyl-4,11-dimethyl-5,12-dioxatricyclo[9.1.0.0⁴,⁶]dodecan-2-yl (2z)-2-methylbut-2-enoate

C22H34O6 (394.2355)


   

2-methoxy-3-[2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]-4-methylidenecyclohexyl 4,5-dihydroxyhex-2-enoate

2-methoxy-3-[2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]-4-methylidenecyclohexyl 4,5-dihydroxyhex-2-enoate

C22H34O6 (394.2355)


   

(1's,2r,2's,4's,7's,8'r,9's,12's)-5,7',9',17'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-13'(18'),14',16'-triene

(1's,2r,2's,4's,7's,8'r,9's,12's)-5,7',9',17'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-13'(18'),14',16'-triene

C27H38O2 (394.2872)


   

(1s,2s,6s,7s,9r,11s,13s,14r,15s,16s,17s)-15,16-dihydroxy-4,11-dimethoxy-2,6,14,17-tetramethyl-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadec-4-en-3-one

(1s,2s,6s,7s,9r,11s,13s,14r,15s,16s,17s)-15,16-dihydroxy-4,11-dimethoxy-2,6,14,17-tetramethyl-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadec-4-en-3-one

C22H34O6 (394.2355)


   

1,3-dihydroxypropan-2-yl 5-(3-hydroxy-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl)-3-methylpent-2-enoate

1,3-dihydroxypropan-2-yl 5-(3-hydroxy-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl)-3-methylpent-2-enoate

C23H38O5 (394.2719)


   

(1r,3r,4r,4as,8as)-4-hydroxy-4-{2-[(2r)-2-hydroxy-5-oxo-2h-furan-3-yl]ethyl}-3,4a,8,8-tetramethyl-hexahydro-1h-naphthalen-1-yl acetate

(1r,3r,4r,4as,8as)-4-hydroxy-4-{2-[(2r)-2-hydroxy-5-oxo-2h-furan-3-yl]ethyl}-3,4a,8,8-tetramethyl-hexahydro-1h-naphthalen-1-yl acetate

C22H34O6 (394.2355)


   

2,12,16-trihydroxy-5-(hydroxymethyl)-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-15-yl acetate

2,12,16-trihydroxy-5-(hydroxymethyl)-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-15-yl acetate

C22H34O6 (394.2355)


   

2,6,11,15-tetrahydroxy-5,5,9-trimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-3-yl acetate

2,6,11,15-tetrahydroxy-5,5,9-trimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-3-yl acetate

C22H34O6 (394.2355)


   

(2s)-2,3-dihydroxypropyl (2s,7z)-2-methoxy-12-methyloctadeca-7,17-dien-5-ynoate

(2s)-2,3-dihydroxypropyl (2s,7z)-2-methoxy-12-methyloctadeca-7,17-dien-5-ynoate

C23H38O5 (394.2719)


   

(2z,6e,10z,14e)-10-[(acetyloxy)methyl]-16-hydroxy-14-(hydroxymethyl)-2,6-dimethylhexadeca-2,6,10,14-tetraenoic acid

(2z,6e,10z,14e)-10-[(acetyloxy)methyl]-16-hydroxy-14-(hydroxymethyl)-2,6-dimethylhexadeca-2,6,10,14-tetraenoic acid

C22H34O6 (394.2355)


   

1-(5,6-dimethylhept-3-en-2-yl)-9a,11a-dimethyl-1h,2h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

1-(5,6-dimethylhept-3-en-2-yl)-9a,11a-dimethyl-1h,2h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

C28H42O (394.3235)


   

(3-{2-[3-(5-hydroxy-4,8-dimethyl-7-methylidenenon-3-en-1-yl)-3-methyloxiran-2-yl]ethyl}-3-methyloxiran-2-yl)methyl acetate

(3-{2-[3-(5-hydroxy-4,8-dimethyl-7-methylidenenon-3-en-1-yl)-3-methyloxiran-2-yl]ethyl}-3-methyloxiran-2-yl)methyl acetate

C23H38O5 (394.2719)


   

(2r)-2,8-dimethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]chromen-6-ol

(2r)-2,8-dimethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]chromen-6-ol

C27H38O2 (394.2872)


   

[(1r,2s,5r,6r,7r,9r,12s,13r)-5,9,13-trihydroxy-6-(hydroxymethyl)-2,6-dimethyltetracyclo[10.3.1.0¹,¹⁰.0²,⁷]hexadec-10-en-13-yl]methyl acetate

[(1r,2s,5r,6r,7r,9r,12s,13r)-5,9,13-trihydroxy-6-(hydroxymethyl)-2,6-dimethyltetracyclo[10.3.1.0¹,¹⁰.0²,⁷]hexadec-10-en-13-yl]methyl acetate

C22H34O6 (394.2355)


   

ethyl (8e,16s)-16-methoxytricos-8-en-4,6,17,19-tetraynoate

ethyl (8e,16s)-16-methoxytricos-8-en-4,6,17,19-tetraynoate

C26H34O3 (394.2508)


   

[(1s,2s,5r,6r,7r,10r,12r,13r)-5,13-dihydroxy-6-(hydroxymethyl)-2,6-dimethyl-8-oxotetracyclo[10.3.1.0¹,¹⁰.0²,⁷]hexadecan-13-yl]methyl acetate

[(1s,2s,5r,6r,7r,10r,12r,13r)-5,13-dihydroxy-6-(hydroxymethyl)-2,6-dimethyl-8-oxotetracyclo[10.3.1.0¹,¹⁰.0²,⁷]hexadecan-13-yl]methyl acetate

C22H34O6 (394.2355)


   

(1s,2s,4s,4ar,5's,5''r,8ar)-5''-methoxy-2,5,5,8a-tetramethyl-hexahydro-2h-dispiro[naphthalene-1,2':5',3''-bis(oxolane)]-4-yl acetate

(1s,2s,4s,4ar,5's,5''r,8ar)-5''-methoxy-2,5,5,8a-tetramethyl-hexahydro-2h-dispiro[naphthalene-1,2':5',3''-bis(oxolane)]-4-yl acetate

C23H38O5 (394.2719)


   

(1s,2s,4s,4ar,5'r,5''s,8ar)-5''-methoxy-2,5,5,8a-tetramethyl-hexahydro-2h-dispiro[naphthalene-1,2':5',3''-bis(oxolane)]-4-yl acetate

(1s,2s,4s,4ar,5'r,5''s,8ar)-5''-methoxy-2,5,5,8a-tetramethyl-hexahydro-2h-dispiro[naphthalene-1,2':5',3''-bis(oxolane)]-4-yl acetate

C23H38O5 (394.2719)


   

(2s)-5-[(2s,5e,7e,9s,10r,11e)-2,10-dihydroxy-9,11-dimethyltrideca-5,7,11-trien-1-yl]-2-hydroxy-2-[(1s)-1-hydroxyethyl]-4-methylfuran-3-one

(2s)-5-[(2s,5e,7e,9s,10r,11e)-2,10-dihydroxy-9,11-dimethyltrideca-5,7,11-trien-1-yl]-2-hydroxy-2-[(1s)-1-hydroxyethyl]-4-methylfuran-3-one

C22H34O6 (394.2355)


   

3-{[(4ar,5s,6r,8ar)-5-[(3s)-5-hydroxy-3-methylpentyl]-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]methoxy}-3-oxopropanoic acid

3-{[(4ar,5s,6r,8ar)-5-[(3s)-5-hydroxy-3-methylpentyl]-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]methoxy}-3-oxopropanoic acid

C23H38O5 (394.2719)


   

2-[2-(acetyloxy)ethenyl]-6,10,14-trimethylpentadec-1-en-1-yl acetate

2-[2-(acetyloxy)ethenyl]-6,10,14-trimethylpentadec-1-en-1-yl acetate

C24H42O4 (394.3083)


   

(2z)-5-[(7r)-7-[(1r,4z)-1,6-dihydroxy-4-methylhex-4-en-1-yl]-7-methyl-2-oxo-5,6-dihydrooxepin-3-yl]-2-methylpent-2-en-1-yl acetate

(2z)-5-[(7r)-7-[(1r,4z)-1,6-dihydroxy-4-methylhex-4-en-1-yl]-7-methyl-2-oxo-5,6-dihydrooxepin-3-yl]-2-methylpent-2-en-1-yl acetate

C22H34O6 (394.2355)


   

(1r,2r,5s,10r,12r,13s,16s)-14-hydroxy-8-isopropyl-12,16-dimethoxy-2-methyl-15-oxatetracyclo[11.2.1.0²,¹⁰.0⁵,⁹]hexadec-8-ene-5-carboxylic acid

(1r,2r,5s,10r,12r,13s,16s)-14-hydroxy-8-isopropyl-12,16-dimethoxy-2-methyl-15-oxatetracyclo[11.2.1.0²,¹⁰.0⁵,⁹]hexadec-8-ene-5-carboxylic acid

C22H34O6 (394.2355)


   

1,3-bis(acetyloxy)propan-2-yl 3-methyl-5-(2,6,6-trimethylcyclohex-1-en-1-yl)pent-2-enoate

1,3-bis(acetyloxy)propan-2-yl 3-methyl-5-(2,6,6-trimethylcyclohex-1-en-1-yl)pent-2-enoate

C22H34O6 (394.2355)


   

(1r,9as,10r,11ar)-1-[(2r,3e,5r)-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-10-ol

(1r,9as,10r,11ar)-1-[(2r,3e,5r)-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-10-ol

C28H42O (394.3235)


   

(1r,2s,4ar,8ar)-1-(acetyloxy)-7-(2-hydroxypropan-2-yl)-1,4a-dimethyl-6-oxo-3,4,5,8a-tetrahydro-2h-naphthalen-2-yl (2r)-2-methylbutanoate

(1r,2s,4ar,8ar)-1-(acetyloxy)-7-(2-hydroxypropan-2-yl)-1,4a-dimethyl-6-oxo-3,4,5,8a-tetrahydro-2h-naphthalen-2-yl (2r)-2-methylbutanoate

C22H34O6 (394.2355)


   

10-[(acetyloxy)methyl]-16-hydroxy-14-(hydroxymethyl)-2,6-dimethylhexadeca-2,6,10,14-tetraenoic acid

10-[(acetyloxy)methyl]-16-hydroxy-14-(hydroxymethyl)-2,6-dimethylhexadeca-2,6,10,14-tetraenoic acid

C22H34O6 (394.2355)


   

3-{[5-(2-hydroxy-2,5,5,8a-tetramethyl-hexahydro-1h-naphthalen-1-yl)-3-methylpent-2-en-1-yl]oxy}-3-oxopropanoic acid

3-{[5-(2-hydroxy-2,5,5,8a-tetramethyl-hexahydro-1h-naphthalen-1-yl)-3-methylpent-2-en-1-yl]oxy}-3-oxopropanoic acid

C23H38O5 (394.2719)


   

2-methyl-6-[(2e,6e,10e)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]cyclohexa-2,5-diene-1,4-dione

2-methyl-6-[(2e,6e,10e)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]cyclohexa-2,5-diene-1,4-dione

C27H38O2 (394.2872)


   

15-epileoheteronone e

NA

C22H34O6 (394.2355)


{"Ingredient_id": "HBIN001671","Ingredient_name": "15-epileoheteronone e","Alias": "NA","Ingredient_formula": "C22H34O6","Ingredient_Smile": "CC(=O)OC1(C(=O)CC2C(CCCC2(C13CCC4(O3)CC(OC4)O)C)(C)C)C","Ingredient_weight": "394.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT15261","TCMID_id": "6944","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "101774203","DrugBank_id": "NA"}

   

15-epileopersin b

NA

C22H34O6 (394.2355)


{"Ingredient_id": "HBIN001672","Ingredient_name": "15-epileopersin b","Alias": "NA","Ingredient_formula": "C22H34O6","Ingredient_Smile": "CC(=O)OC1(C(=O)CC2C(CCCC2(C13CCC4(O3)CC(OC4)O)C)(C)C)C","Ingredient_weight": "394.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT15262","TCMID_id": "6945","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "101685704","DrugBank_id": "NA"}

   

16,17-dihydrorostronol f

NA

C22H34O6 (394.2355)


{"Ingredient_id": "HBIN001745","Ingredient_name": "16,17-dihydrorostronol f","Alias": "NA","Ingredient_formula": "C22H34O6","Ingredient_Smile": "CC1C2CC(C3C4(CCCC(C4CC(C3(C2O)C1=O)O)(C)C)CO)OC(=O)C","Ingredient_weight": "394.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "5702","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "637202","DrugBank_id": "NA"}

   

6-methylgingediacetate

NA

C22H34O6 (394.2355)


{"Ingredient_id": "HBIN012563","Ingredient_name": "6-methylgingediacetate","Alias": "NA","Ingredient_formula": "C22H34O6","Ingredient_Smile": "CCCCCC(CC(CCC1=CC(=C(C=C1)OC)OC)OC(=O)C)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "14455","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

7-debenzoyloxy-10-deacetyl-brevifoliol

NA

C22H34O6 (394.2355)


{"Ingredient_id": "HBIN013146","Ingredient_name": "7-debenzoyloxy-10-deacetyl-brevifoliol","Alias": "NA","Ingredient_formula": "C22H34O6","Ingredient_Smile": "CC1=C2C(C(C3(CCC(C(=C)C3CC2(CC1O)C(C)(C)O)O)C)OC(=O)C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4807","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

7-debenzoyloxy-10-deacetyl-brevifoliol(i)

NA

C22H34O6 (394.2355)


{"Ingredient_id": "HBIN013147","Ingredient_name": "7-debenzoyloxy-10-deacetyl-brevifoliol(i)","Alias": "NA","Ingredient_formula": "C22H34O6","Ingredient_Smile": "CC1=C2C(C(C3(CCC(C(=C)C3CC2(CC1O)C(C)(C)O)O)C)OC(=O)C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "26016","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

7-debenzoyloxy-10-deacetyl-brevifoliol(ii)

NA

C22H34O6 (394.2355)


{"Ingredient_id": "HBIN013148","Ingredient_name": "7-debenzoyloxy-10-deacetyl-brevifoliol(ii)","Alias": "NA","Ingredient_formula": "C22H34O6","Ingredient_Smile": "CC1=C2C(C(C3(CCC(C(=C)C3CC2(CC1O)C(C)(C)O)O)C)OC(=O)C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "26015","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

methyl 2-(acetyloxy)-5-(5-hydroxy-3-methylpentyl)-1,4a-dimethyl-6-methylidene-hexahydro-2h-naphthalene-1-carboxylate

methyl 2-(acetyloxy)-5-(5-hydroxy-3-methylpentyl)-1,4a-dimethyl-6-methylidene-hexahydro-2h-naphthalene-1-carboxylate

C23H38O5 (394.2719)


   

3,4,6,14-tetrahydroxy-5,5,14-trimethyl-9-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-16-yl acetate

3,4,6,14-tetrahydroxy-5,5,14-trimethyl-9-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-16-yl acetate

C22H34O6 (394.2355)


   

(1s,2s,4s,4ar,5'r,5''r,8ar)-5''-methoxy-2,5,5,8a-tetramethyl-hexahydro-2h-dispiro[naphthalene-1,2':5',3''-bis(oxolane)]-4-yl acetate

(1s,2s,4s,4ar,5'r,5''r,8ar)-5''-methoxy-2,5,5,8a-tetramethyl-hexahydro-2h-dispiro[naphthalene-1,2':5',3''-bis(oxolane)]-4-yl acetate

C23H38O5 (394.2719)


   

2-(acetyloxy)-5-hydroxy-5-isopropyl-2a,7a-dimethyl-hexahydro-1ah-azuleno[5,6-b]oxiren-6-yl 2-methylbut-2-enoate

2-(acetyloxy)-5-hydroxy-5-isopropyl-2a,7a-dimethyl-hexahydro-1ah-azuleno[5,6-b]oxiren-6-yl 2-methylbut-2-enoate

C22H34O6 (394.2355)


   

14-hydroperoxy-5,8,11-trimethyl-15-methylidene-10,18-dioxatetracyclo[9.7.0.0²,⁷.0³,¹⁷]octadecan-4-yl acetate

14-hydroperoxy-5,8,11-trimethyl-15-methylidene-10,18-dioxatetracyclo[9.7.0.0²,⁷.0³,¹⁷]octadecan-4-yl acetate

C22H34O6 (394.2355)


   

(1r,2s,4r,5s,6r,9r,10r,13r,14r,16r)-2-hydroxy-5,14-bis(hydroxymethyl)-5,9-dimethyl-15-oxapentacyclo[11.3.1.0¹,¹⁰.0⁴,⁹.0¹⁴,¹⁶]heptadecan-6-yl acetate

(1r,2s,4r,5s,6r,9r,10r,13r,14r,16r)-2-hydroxy-5,14-bis(hydroxymethyl)-5,9-dimethyl-15-oxapentacyclo[11.3.1.0¹,¹⁰.0⁴,⁹.0¹⁴,¹⁶]heptadecan-6-yl acetate

C22H34O6 (394.2355)


   

(1r,3ar,7s,9ar,9bs,11ar)-1-[(2r,3e,5s)-5,6-dimethylhepta-3,6-dien-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

(1r,3ar,7s,9ar,9bs,11ar)-1-[(2r,3e,5s)-5,6-dimethylhepta-3,6-dien-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

C28H42O (394.3235)


   

(2z,5e,7r)-7-hydroxy-2-[(4e)-6-hydroxy-4-(hydroxymethyl)hex-4-en-1-ylidene]-6,10-dimethyl-9-methylideneundec-5-en-1-yl acetate

(2z,5e,7r)-7-hydroxy-2-[(4e)-6-hydroxy-4-(hydroxymethyl)hex-4-en-1-ylidene]-6,10-dimethyl-9-methylideneundec-5-en-1-yl acetate

C23H38O5 (394.2719)


   

13-[(acetyloxy)methyl]-5,13-dihydroxy-2,6-dimethyltetracyclo[10.3.1.0¹,¹⁰.0²,⁷]hexadecane-6-carboxylic acid

13-[(acetyloxy)methyl]-5,13-dihydroxy-2,6-dimethyltetracyclo[10.3.1.0¹,¹⁰.0²,⁷]hexadecane-6-carboxylic acid

C22H34O6 (394.2355)


   

3-ethenyl-6,10-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-octahydronaphtho[2,1-b]pyran-5-yl acetate

3-ethenyl-6,10-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-octahydronaphtho[2,1-b]pyran-5-yl acetate

C22H34O6 (394.2355)


   

(2s)-2,8-dimethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]chromen-6-ol

(2s)-2,8-dimethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]chromen-6-ol

C27H38O2 (394.2872)


   

(1s,4s,4as,5'r,8as)-2-[(acetyloxy)methyl]-4-hydroxy-5,5,5',8a-tetramethyl-4a,6,7,8-tetrahydro-4h-spiro[naphthalene-1,2'-oxolan]-5'-ylacetic acid

(1s,4s,4as,5'r,8as)-2-[(acetyloxy)methyl]-4-hydroxy-5,5,5',8a-tetramethyl-4a,6,7,8-tetrahydro-4h-spiro[naphthalene-1,2'-oxolan]-5'-ylacetic acid

C22H34O6 (394.2355)


   

(1r,3ar,7s,9as,11ar)-1-[(2r,3e,5s)-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-ol

(1r,3ar,7s,9as,11ar)-1-[(2r,3e,5s)-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-ol

C28H42O (394.3235)


   

3-ethenyl-6,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-hexahydro-2h-naphtho[2,1-b]pyran-5-yl acetate

3-ethenyl-6,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-hexahydro-2h-naphtho[2,1-b]pyran-5-yl acetate

C22H34O6 (394.2355)


   

(1s,3s,4r,6s,8s,10s,13r,14r,16r)-3,4,6,14-tetrahydroxy-5,5,14-trimethyl-9-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-16-yl acetate

(1s,3s,4r,6s,8s,10s,13r,14r,16r)-3,4,6,14-tetrahydroxy-5,5,14-trimethyl-9-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-16-yl acetate

C22H34O6 (394.2355)


   

(1s,4r,6s,8s,9r,10r,11s)-10-(acetyloxy)-9-isopropyl-1,6-dimethyl-5,12-dioxatricyclo[9.1.0.0⁴,⁶]dodecan-8-yl (2z)-2-methylbut-2-enoate

(1s,4r,6s,8s,9r,10r,11s)-10-(acetyloxy)-9-isopropyl-1,6-dimethyl-5,12-dioxatricyclo[9.1.0.0⁴,⁶]dodecan-8-yl (2z)-2-methylbut-2-enoate

C22H34O6 (394.2355)


   

5-[7-(acetyloxy)-5-formyl-6-hydroxy-2,5,8a-trimethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]-3-methylpentanoic acid

5-[7-(acetyloxy)-5-formyl-6-hydroxy-2,5,8a-trimethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]-3-methylpentanoic acid

C22H34O6 (394.2355)


   

(2s)-11-(3,5-diethyl-6-methoxy-4-oxopyran-2-yl)undecan-2-yl acetate

(2s)-11-(3,5-diethyl-6-methoxy-4-oxopyran-2-yl)undecan-2-yl acetate

C23H38O5 (394.2719)


   

(2as,5r,7ar)-2-(acetyloxy)-5-hydroxy-5-isopropyl-2a,7a-dimethyl-hexahydro-1ah-azuleno[5,6-b]oxiren-6-yl 2-methylbut-2-enoate

(2as,5r,7ar)-2-(acetyloxy)-5-hydroxy-5-isopropyl-2a,7a-dimethyl-hexahydro-1ah-azuleno[5,6-b]oxiren-6-yl 2-methylbut-2-enoate

C22H34O6 (394.2355)


   

(1r,3r,3as,4s,5s,7as)-4,5,7-triethyl-1,3-dimethyl-2-oxo-5-[(1e)-2-phenylethenyl]-1,3,3a,7a-tetrahydroindene-4-carboxylic acid

(1r,3r,3as,4s,5s,7as)-4,5,7-triethyl-1,3-dimethyl-2-oxo-5-[(1e)-2-phenylethenyl]-1,3,3a,7a-tetrahydroindene-4-carboxylic acid

C26H34O3 (394.2508)


   

(2s)-2-[(3r,6s)-6-[6-(2,2-dimethyl-6-methylidenecyclohexyl)-4-methylhexyl]-6-methyl-1,2-dioxan-3-yl]propanoic acid

(2s)-2-[(3r,6s)-6-[6-(2,2-dimethyl-6-methylidenecyclohexyl)-4-methylhexyl]-6-methyl-1,2-dioxan-3-yl]propanoic acid

C24H42O4 (394.3083)


   

3-ethenyl-6,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-hexahydro-2h-naphtho[2,1-b]pyran-10-yl acetate

3-ethenyl-6,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-hexahydro-2h-naphtho[2,1-b]pyran-10-yl acetate

C22H34O6 (394.2355)


   

5''-methoxy-2,5,5,8a-tetramethyl-hexahydro-2h-dispiro[naphthalene-1,2':5',3''-bis(oxolane)]-4-yl acetate

5''-methoxy-2,5,5,8a-tetramethyl-hexahydro-2h-dispiro[naphthalene-1,2':5',3''-bis(oxolane)]-4-yl acetate

C23H38O5 (394.2719)


   

[(1r,2s,5s,7s,9r,11s,13r)-11-(acetyloxy)-5-ethenyl-1,5,7,12,12-pentamethyl-6,8-dioxatricyclo[7.4.0.0²,⁷]tridecan-13-yl]acetic acid

[(1r,2s,5s,7s,9r,11s,13r)-11-(acetyloxy)-5-ethenyl-1,5,7,12,12-pentamethyl-6,8-dioxatricyclo[7.4.0.0²,⁷]tridecan-13-yl]acetic acid

C22H34O6 (394.2355)


   

(1s,2s,6s,7s,9r,13s,14r,15s,16s,17s)-11,16-dihydroxy-4,15-dimethoxy-2,6,14,17-tetramethyl-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadec-4-en-3-one

(1s,2s,6s,7s,9r,13s,14r,15s,16s,17s)-11,16-dihydroxy-4,15-dimethoxy-2,6,14,17-tetramethyl-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadec-4-en-3-one

C22H34O6 (394.2355)


   

(4s)-3,4-dihydroxy-2-octadecanoylcyclohex-2-en-1-one

(4s)-3,4-dihydroxy-2-octadecanoylcyclohex-2-en-1-one

C24H42O4 (394.3083)


   

1-(5,6-dimethylhept-3-en-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-ol

1-(5,6-dimethylhept-3-en-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-ol

C28H42O (394.3235)


   

2-methyl-6-(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl)cyclohexa-2,5-diene-1,4-dione

2-methyl-6-(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl)cyclohexa-2,5-diene-1,4-dione

C27H38O2 (394.2872)


   

(1s,3s,3ar,4r,5s,7ar)-1,4,5-triethyl-3,7-dimethyl-2-oxo-5-[(1e)-2-phenylethenyl]-1,3,3a,7a-tetrahydroindene-4-carboxylic acid

(1s,3s,3ar,4r,5s,7ar)-1,4,5-triethyl-3,7-dimethyl-2-oxo-5-[(1e)-2-phenylethenyl]-1,3,3a,7a-tetrahydroindene-4-carboxylic acid

C26H34O3 (394.2508)


   

(4r,5r,6s,7r,9s,11e,13e,15s,16r)-7,16-diethyl-4,6-dihydroxy-5,9,13,15-tetramethyl-1-oxacyclohexadeca-11,13-diene-2,10-dione

(4r,5r,6s,7r,9s,11e,13e,15s,16r)-7,16-diethyl-4,6-dihydroxy-5,9,13,15-tetramethyl-1-oxacyclohexadeca-11,13-diene-2,10-dione

C23H38O5 (394.2719)


   

(1r,3br,4r,5ar,9ar,9br,11as)-1-(furan-3-yl)-4-hydroxy-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

(1r,3br,4r,5ar,9ar,9br,11as)-1-(furan-3-yl)-4-hydroxy-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

C26H34O3 (394.2508)


   

(1s,2s,4s,4ar,5's,5''s,8ar)-5''-methoxy-2,5,5,8a-tetramethyl-hexahydro-2h-dispiro[naphthalene-1,2':5',3''-bis(oxolane)]-4-yl acetate

(1s,2s,4s,4ar,5's,5''s,8ar)-5''-methoxy-2,5,5,8a-tetramethyl-hexahydro-2h-dispiro[naphthalene-1,2':5',3''-bis(oxolane)]-4-yl acetate

C23H38O5 (394.2719)


   

(1r,7s,9ar,9br,11ar)-1-[(2r,3e,5r)-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

(1r,7s,9ar,9br,11ar)-1-[(2r,3e,5r)-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

C28H42O (394.3235)


   

(1e,3e,7s,11r)-3-[(acetyloxy)methylidene]-7,11,15-trimethylhexadec-1-en-1-yl acetate

(1e,3e,7s,11r)-3-[(acetyloxy)methylidene]-7,11,15-trimethylhexadec-1-en-1-yl acetate

C24H42O4 (394.3083)


   

4,5,7-triethyl-1,3-dimethyl-2-oxo-5-(2-phenylethenyl)-1,3,3a,7a-tetrahydroindene-4-carboxylic acid

4,5,7-triethyl-1,3-dimethyl-2-oxo-5-(2-phenylethenyl)-1,3,3a,7a-tetrahydroindene-4-carboxylic acid

C26H34O3 (394.2508)


   

1-(furan-3-yl)-4-hydroxy-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

1-(furan-3-yl)-4-hydroxy-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

C26H34O3 (394.2508)


   

[(4ar,5r,6s,7r,8ar)-7-hydroxy-5-{2-[(3s,5r)-5-methoxyoxolan-3-yl]ethyl}-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]methyl acetate

[(4ar,5r,6s,7r,8ar)-7-hydroxy-5-{2-[(3s,5r)-5-methoxyoxolan-3-yl]ethyl}-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]methyl acetate

C23H38O5 (394.2719)


   

9a,11a-dimethyl-1-(6-methyl-5-methylideneheptan-2-yl)-1h,2h,3h,3ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-ol

9a,11a-dimethyl-1-(6-methyl-5-methylideneheptan-2-yl)-1h,2h,3h,3ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-ol

C28H42O (394.3235)


   

3-(5,6-dimethylhept-3-en-2-yl)-3a,6-dimethyl-1h,2h,3h,4h,5h,7h,8h,9h,10h,11bh-cyclopenta[a]anthracen-8-ol

3-(5,6-dimethylhept-3-en-2-yl)-3a,6-dimethyl-1h,2h,3h,4h,5h,7h,8h,9h,10h,11bh-cyclopenta[a]anthracen-8-ol

C28H42O (394.3235)


   

2,8-dimethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]chromen-6-ol

2,8-dimethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]chromen-6-ol

C27H38O2 (394.2872)


   

(1's,2r,2's,4's,5r,7's,8'r,9's,12's)-5,7',9',17'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-13'(18'),14',16'-triene

(1's,2r,2's,4's,5r,7's,8'r,9's,12's)-5,7',9',17'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-13'(18'),14',16'-triene

C27H38O2 (394.2872)


   

(1r,3br,4r,5as,9ar,9br,11as)-1-(furan-3-yl)-4-hydroxy-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

(1r,3br,4r,5as,9ar,9br,11as)-1-(furan-3-yl)-4-hydroxy-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

C26H34O3 (394.2508)


   

1-(5,6-dimethylheptan-2-yl)-9a,11a-dimethyl-1h,2h,3h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

1-(5,6-dimethylheptan-2-yl)-9a,11a-dimethyl-1h,2h,3h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

C28H42O (394.3235)


   

(3r,3ar,8s,11br)-3-[(2r,3e,5r)-5,6-dimethylhept-3-en-2-yl]-3a,6-dimethyl-1h,2h,3h,4h,5h,7h,8h,9h,10h,11bh-cyclopenta[a]anthracen-8-ol

(3r,3ar,8s,11br)-3-[(2r,3e,5r)-5,6-dimethylhept-3-en-2-yl]-3a,6-dimethyl-1h,2h,3h,4h,5h,7h,8h,9h,10h,11bh-cyclopenta[a]anthracen-8-ol

C28H42O (394.3235)


   

(2r)-2,7-dimethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]chromen-6-ol

(2r)-2,7-dimethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]chromen-6-ol

C27H38O2 (394.2872)


   

3-{[5-(5-hydroxy-3-methylpentyl)-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]methoxy}-3-oxopropanoic acid

3-{[5-(5-hydroxy-3-methylpentyl)-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]methoxy}-3-oxopropanoic acid

C23H38O5 (394.2719)


   

(1r,3as,3bs,9ar,9bs,11ar)-1-[(2s,3e,5r)-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

(1r,3as,3bs,9ar,9bs,11ar)-1-[(2s,3e,5r)-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

C28H42O (394.3235)


   

(6s)-3,6-dihydroxy-2-octadecanoylcyclohex-2-en-1-one

(6s)-3,6-dihydroxy-2-octadecanoylcyclohex-2-en-1-one

C24H42O4 (394.3083)


   

2,8-dimethyl-2-(4,8,12-trimethyltrideca-3,7,11-trien-1-yl)chromen-6-ol

2,8-dimethyl-2-(4,8,12-trimethyltrideca-3,7,11-trien-1-yl)chromen-6-ol

C27H38O2 (394.2872)


   

(1r,7s,9ar,9br,11ar)-1-[(2s,3e,5r)-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

(1r,7s,9ar,9br,11ar)-1-[(2s,3e,5r)-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

C28H42O (394.3235)


   

1-(5,6-dimethylhepta-3,5-dien-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-8-ol

1-(5,6-dimethylhepta-3,5-dien-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-8-ol

C28H42O (394.3235)


   

ethyl 16-methoxytricos-8-en-4,6,17,19-tetraynoate

ethyl 16-methoxytricos-8-en-4,6,17,19-tetraynoate

C26H34O3 (394.2508)


   

3,4,5-triethyl-1,7-dimethyl-2-oxo-5-(2-phenylethenyl)-1,3,3a,7a-tetrahydroindene-4-carboxylic acid

3,4,5-triethyl-1,7-dimethyl-2-oxo-5-(2-phenylethenyl)-1,3,3a,7a-tetrahydroindene-4-carboxylic acid

C26H34O3 (394.2508)


   

(1e,3e,7s,11s)-3-[(acetyloxy)methylidene]-7,11,15-trimethylhexadec-1-en-1-yl acetate

(1e,3e,7s,11s)-3-[(acetyloxy)methylidene]-7,11,15-trimethylhexadec-1-en-1-yl acetate

C24H42O4 (394.3083)


   

17-(hydroxymethyl)-2,7,7,10-tetramethyl-6,8-dioxapentacyclo[14.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]icosane-12,17-diol

17-(hydroxymethyl)-2,7,7,10-tetramethyl-6,8-dioxapentacyclo[14.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]icosane-12,17-diol

C23H38O5 (394.2719)


   

(1s,2s,3r,4r,5r,7s,8r,11s,14r,15r,17s)-14-methoxy-5,8,11,15-tetramethyl-10,18-dioxatetracyclo[9.7.0.0²,⁷.0³,¹⁷]octadecan-4-yl acetate

(1s,2s,3r,4r,5r,7s,8r,11s,14r,15r,17s)-14-methoxy-5,8,11,15-tetramethyl-10,18-dioxatetracyclo[9.7.0.0²,⁷.0³,¹⁷]octadecan-4-yl acetate

C23H38O5 (394.2719)


   

9a,11a-dimethyl-1-(6-methyl-5-methylidenehept-3-en-2-yl)-1h,2h,3h,3ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

9a,11a-dimethyl-1-(6-methyl-5-methylidenehept-3-en-2-yl)-1h,2h,3h,3ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

C28H42O (394.3235)


   

(1s,5r,6r)-4-[(2r)-5-(2-chloropropan-2-yl)-2-methyloxolan-2-yl]-6-hydroxy-1,6-dimethyl-n1,n5-dimethylidyne-octahydronaphthalene-1,5-bis(aminium)

(1s,5r,6r)-4-[(2r)-5-(2-chloropropan-2-yl)-2-methyloxolan-2-yl]-6-hydroxy-1,6-dimethyl-n1,n5-dimethylidyne-octahydronaphthalene-1,5-bis(aminium)

[C22H35ClN2O2]2+ (394.2387)


   

(1r,3as,3br,5as,9as,9bs,11as)-1-hydroxy-1-[(1r)-1-hydroxyethyl]-7,7-dimethoxy-9a,11a-dimethyl-dodecahydrocyclopenta[a]phenanthren-2-one

(1r,3as,3br,5as,9as,9bs,11as)-1-hydroxy-1-[(1r)-1-hydroxyethyl]-7,7-dimethoxy-9a,11a-dimethyl-dodecahydrocyclopenta[a]phenanthren-2-one

C23H38O5 (394.2719)


   

2-methyl-5-[(2e,6e,10e)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]cyclohexa-2,5-diene-1,4-dione

2-methyl-5-[(2e,6e,10e)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]cyclohexa-2,5-diene-1,4-dione

C27H38O2 (394.2872)


   

[(2r,3r)-3-{2-[(2r,3s)-3-[(3e,5r)-5-hydroxy-4,8-dimethyl-7-methylidenenon-3-en-1-yl]-3-methyloxiran-2-yl]ethyl}-3-methyloxiran-2-yl]methyl acetate

[(2r,3r)-3-{2-[(2r,3s)-3-[(3e,5r)-5-hydroxy-4,8-dimethyl-7-methylidenenon-3-en-1-yl]-3-methyloxiran-2-yl]ethyl}-3-methyloxiran-2-yl]methyl acetate

C23H38O5 (394.2719)


   

11-(3,5-diethyl-6-methoxy-4-oxopyran-2-yl)undecan-2-yl acetate

11-(3,5-diethyl-6-methoxy-4-oxopyran-2-yl)undecan-2-yl acetate

C23H38O5 (394.2719)


   

14-methoxy-5,8,11,15-tetramethyl-10,18-dioxatetracyclo[9.7.0.0²,⁷.0³,¹⁷]octadecan-4-yl acetate

14-methoxy-5,8,11,15-tetramethyl-10,18-dioxatetracyclo[9.7.0.0²,⁷.0³,¹⁷]octadecan-4-yl acetate

C23H38O5 (394.2719)


   

icosyl 2,2,2-trifluoroacetate

icosyl 2,2,2-trifluoroacetate

C22H41F3O2 (394.3058)


   

(2r)-2-[(3s,6r)-6-[(4r)-6-[(1r)-2,2-dimethyl-6-methylidenecyclohexyl]-4-methylhexyl]-6-methyl-1,2-dioxan-3-yl]propanoic acid

(2r)-2-[(3s,6r)-6-[(4r)-6-[(1r)-2,2-dimethyl-6-methylidenecyclohexyl]-4-methylhexyl]-6-methyl-1,2-dioxan-3-yl]propanoic acid

C24H42O4 (394.3083)


   

(1r,3ar,7s,9ar,9bs,11ar)-9a,11a-dimethyl-1-[(2r,3e)-6-methyl-5-methylidenehept-3-en-2-yl]-1h,2h,3h,3ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

(1r,3ar,7s,9ar,9bs,11ar)-9a,11a-dimethyl-1-[(2r,3e)-6-methyl-5-methylidenehept-3-en-2-yl]-1h,2h,3h,3ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

C28H42O (394.3235)


   

(1r,3as,3bs,9ar,9bs,11ar)-1-[(2r,3e,5s)-5,6-dimethylhepta-3,6-dien-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

(1r,3as,3bs,9ar,9bs,11ar)-1-[(2r,3e,5s)-5,6-dimethylhepta-3,6-dien-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

C28H42O (394.3235)


   

1,4,5-triethyl-3,7-dimethyl-2-oxo-5-(2-phenylethenyl)-1,3,3a,7a-tetrahydroindene-4-carboxylic acid

1,4,5-triethyl-3,7-dimethyl-2-oxo-5-(2-phenylethenyl)-1,3,3a,7a-tetrahydroindene-4-carboxylic acid

C26H34O3 (394.2508)


   

6-[(1r,3as,3br,9as,9bs,11as)-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylidenehepta-1,4,6-trien-1-ol

6-[(1r,3as,3br,9as,9bs,11as)-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylidenehepta-1,4,6-trien-1-ol

C28H42O (394.3235)


   

(2s)-2-[(3r,6r)-6-[(4r)-6-[(1s)-2,2-dimethyl-6-methylidenecyclohexyl]-4-methylhexyl]-6-methyl-1,2-dioxan-3-yl]propanoic acid

(2s)-2-[(3r,6r)-6-[(4r)-6-[(1s)-2,2-dimethyl-6-methylidenecyclohexyl]-4-methylhexyl]-6-methyl-1,2-dioxan-3-yl]propanoic acid

C24H42O4 (394.3083)


   

3-{[(2e)-5-[(1r,2r,4as,8as)-2-hydroxy-2,5,5,8a-tetramethyl-hexahydro-1h-naphthalen-1-yl]-3-methylpent-2-en-1-yl]oxy}-3-oxopropanoic acid

3-{[(2e)-5-[(1r,2r,4as,8as)-2-hydroxy-2,5,5,8a-tetramethyl-hexahydro-1h-naphthalen-1-yl]-3-methylpent-2-en-1-yl]oxy}-3-oxopropanoic acid

C23H38O5 (394.2719)


   

{7-hydroxy-5-[2-(5-methoxyoxolan-3-yl)ethyl]-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl}methyl acetate

{7-hydroxy-5-[2-(5-methoxyoxolan-3-yl)ethyl]-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl}methyl acetate

C23H38O5 (394.2719)


   

(1r,3as,3bs,9ar,9bs,11ar)-1-[(2r,3e,5s)-5,6-dimethylhepta-3,6-dien-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

(1r,3as,3bs,9ar,9bs,11ar)-1-[(2r,3e,5s)-5,6-dimethylhepta-3,6-dien-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

C28H42O (394.3235)


   

5,7',9',17'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-13'(18'),14',16'-triene

5,7',9',17'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-13'(18'),14',16'-triene

C27H38O2 (394.2872)


   

(2s)-2,3-dihydroxypropyl (2s)-2-methoxy-12-methyloctadeca-7,17-dien-5-ynoate

(2s)-2,3-dihydroxypropyl (2s)-2-methoxy-12-methyloctadeca-7,17-dien-5-ynoate

C23H38O5 (394.2719)


   

(1r,3as,3br,4r,5ar,7r,9as,9bs,11s,11ar)-1-[(2s)-5-hydroxypentan-2-yl]-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthrene-4,7,11-triol

(1r,3as,3br,4r,5ar,7r,9as,9bs,11s,11ar)-1-[(2s)-5-hydroxypentan-2-yl]-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthrene-4,7,11-triol

C24H42O4 (394.3083)


   

(1s,3s,3ar,4r,5s,7ar)-3,4,5-triethyl-1,7-dimethyl-2-oxo-5-[(1e)-2-phenylethenyl]-1,3,3a,7a-tetrahydroindene-4-carboxylic acid

(1s,3s,3ar,4r,5s,7ar)-3,4,5-triethyl-1,7-dimethyl-2-oxo-5-[(1e)-2-phenylethenyl]-1,3,3a,7a-tetrahydroindene-4-carboxylic acid

C26H34O3 (394.2508)


   

(1s,3as,3bs,4r,7r,8r,9ar,9bs,11as)-1-[(1s)-1-hydroxy-2-methoxyethyl]-7-methoxy-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-4,8-diol

(1s,3as,3bs,4r,7r,8r,9ar,9bs,11as)-1-[(1s)-1-hydroxy-2-methoxyethyl]-7-methoxy-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-4,8-diol

C23H38O5 (394.2719)


   

1-(1-hydroxy-2-methoxyethyl)-7-methoxy-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-4,8-diol

1-(1-hydroxy-2-methoxyethyl)-7-methoxy-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-4,8-diol

C23H38O5 (394.2719)


   

7-hydroxy-2-[6-hydroxy-4-(hydroxymethyl)hex-4-en-1-ylidene]-6,10-dimethyl-9-methylideneundec-5-en-1-yl acetate

7-hydroxy-2-[6-hydroxy-4-(hydroxymethyl)hex-4-en-1-ylidene]-6,10-dimethyl-9-methylideneundec-5-en-1-yl acetate

C23H38O5 (394.2719)


   

methyl (1r,2r,4ar,5s,8ar)-2-(acetyloxy)-5-[(3s)-5-hydroxy-3-methylpentyl]-1,4a-dimethyl-6-methylidene-hexahydro-2h-naphthalene-1-carboxylate

methyl (1r,2r,4ar,5s,8ar)-2-(acetyloxy)-5-[(3s)-5-hydroxy-3-methylpentyl]-1,4a-dimethyl-6-methylidene-hexahydro-2h-naphthalene-1-carboxylate

C23H38O5 (394.2719)


   

7,16-diethyl-4,6-dihydroxy-5,9,13,15-tetramethyl-1-oxacyclohexadeca-11,13-diene-2,10-dione

7,16-diethyl-4,6-dihydroxy-5,9,13,15-tetramethyl-1-oxacyclohexadeca-11,13-diene-2,10-dione

C23H38O5 (394.2719)


   

1-(5,6-dimethylhepta-3,6-dien-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

1-(5,6-dimethylhepta-3,6-dien-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

C28H42O (394.3235)


   

(1r,3ar,7s,9as,11ar)-9a,11a-dimethyl-1-[(2r)-6-methyl-5-methylideneheptan-2-yl]-1h,2h,3h,3ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-ol

(1r,3ar,7s,9as,11ar)-9a,11a-dimethyl-1-[(2r)-6-methyl-5-methylideneheptan-2-yl]-1h,2h,3h,3ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-ol

C28H42O (394.3235)


   

(1s,2s,5r,10r,11r,12s,14r,16r,17r)-17-(hydroxymethyl)-2,7,7,10-tetramethyl-6,8-dioxapentacyclo[14.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]icosane-12,17-diol

(1s,2s,5r,10r,11r,12s,14r,16r,17r)-17-(hydroxymethyl)-2,7,7,10-tetramethyl-6,8-dioxapentacyclo[14.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]icosane-12,17-diol

C23H38O5 (394.2719)


   

(1r,3as,7s,9as,11ar)-1-[(2r,3e,5s)-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-ol

(1r,3as,7s,9as,11ar)-1-[(2r,3e,5s)-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-ol

C28H42O (394.3235)


   

(1s,2s,3s,4r,5r,7s,8s,11s,14r,15r,17s)-14-methoxy-5,8,11,15-tetramethyl-10,18-dioxatetracyclo[9.7.0.0²,⁷.0³,¹⁷]octadecan-4-yl acetate

(1s,2s,3s,4r,5r,7s,8s,11s,14r,15r,17s)-14-methoxy-5,8,11,15-tetramethyl-10,18-dioxatetracyclo[9.7.0.0²,⁷.0³,¹⁷]octadecan-4-yl acetate

C23H38O5 (394.2719)


   

(1r,9ar,9br,11ar)-1-[(2r,5r)-5,6-dimethylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

(1r,9ar,9br,11ar)-1-[(2r,5r)-5,6-dimethylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

C28H42O (394.3235)


   

(3s,6s,9s,14as)-3-[(2s)-butan-2-yl]-1,4,7-trihydroxy-6-methyl-9-(2-methylpropyl)-3h,6h,9h,12h,13h,14h,14ah-pyrrolo[1,2-a]1,4,7,10-tetraazacyclododecan-10-one

(3s,6s,9s,14as)-3-[(2s)-butan-2-yl]-1,4,7-trihydroxy-6-methyl-9-(2-methylpropyl)-3h,6h,9h,12h,13h,14h,14ah-pyrrolo[1,2-a]1,4,7,10-tetraazacyclododecan-10-one

C20H34N4O4 (394.258)


   

[(1r,3as,3bs,9as,9bs,11ar)-11a-methyl-1-[(2r)-6-methyl-5-methylideneheptan-2-yl]-1h,2h,3h,3ah,3bh,9h,9bh,10h,11h-cyclopenta[a]phenanthren-9a-yl]methanol

[(1r,3as,3bs,9as,9bs,11ar)-11a-methyl-1-[(2r)-6-methyl-5-methylideneheptan-2-yl]-1h,2h,3h,3ah,3bh,9h,9bh,10h,11h-cyclopenta[a]phenanthren-9a-yl]methanol

C28H42O (394.3235)


   

1-(5-hydroxypentan-2-yl)-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthrene-4,7,11-triol

1-(5-hydroxypentan-2-yl)-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthrene-4,7,11-triol

C24H42O4 (394.3083)


   

(1r,3as,3bs,9ar,9bs,11ar)-1-[(2r,3e,5r)-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

(1r,3as,3bs,9ar,9bs,11ar)-1-[(2r,3e,5r)-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

C28H42O (394.3235)


   

1-(5,6-dimethylhept-3-en-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

1-(5,6-dimethylhept-3-en-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

C28H42O (394.3235)


   

3,6-dihydroxy-2-octadecanoylcyclohex-2-en-1-one

3,6-dihydroxy-2-octadecanoylcyclohex-2-en-1-one

C24H42O4 (394.3083)


   

[(4ar,5r,6s,7r,8ar)-7-hydroxy-5-{2-[(3s,5s)-5-methoxyoxolan-3-yl]ethyl}-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]methyl acetate

[(4ar,5r,6s,7r,8ar)-7-hydroxy-5-{2-[(3s,5s)-5-methoxyoxolan-3-yl]ethyl}-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]methyl acetate

C23H38O5 (394.2719)


   

1-(5,6-dimethylhepta-3,6-dien-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

1-(5,6-dimethylhepta-3,6-dien-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

C28H42O (394.3235)


   

2-[(2e,4e)-5,9-dimethyl-2-(6-methylhept-5-en-2-ylidene)deca-4,8-dien-1-yl]-6-methylcyclohexa-2,5-diene-1,4-dione

2-[(2e,4e)-5,9-dimethyl-2-(6-methylhept-5-en-2-ylidene)deca-4,8-dien-1-yl]-6-methylcyclohexa-2,5-diene-1,4-dione

C27H38O2 (394.2872)


   

(1r,3r,3as,4s,5r,7as)-4,5,7-triethyl-1,3-dimethyl-2-oxo-5-[(1e)-2-phenylethenyl]-1,3,3a,7a-tetrahydroindene-4-carboxylic acid

(1r,3r,3as,4s,5r,7as)-4,5,7-triethyl-1,3-dimethyl-2-oxo-5-[(1e)-2-phenylethenyl]-1,3,3a,7a-tetrahydroindene-4-carboxylic acid

C26H34O3 (394.2508)


   

2,7-dimethyl-2-(4,8,12-trimethyltrideca-3,7,11-trien-1-yl)chromen-6-ol

2,7-dimethyl-2-(4,8,12-trimethyltrideca-3,7,11-trien-1-yl)chromen-6-ol

C27H38O2 (394.2872)


   

1,3-dihydroxypropan-2-yl (2e)-5-[(1s,2r,3s,4as,8as)-3-hydroxy-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]-3-methylpent-2-enoate

1,3-dihydroxypropan-2-yl (2e)-5-[(1s,2r,3s,4as,8as)-3-hydroxy-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]-3-methylpent-2-enoate

C23H38O5 (394.2719)


   

(1r,3ar,7s,11ar)-1-[(2r,3e,5r)-5,6-dimethylhept-3-en-2-yl]-5,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-ol

(1r,3ar,7s,11ar)-1-[(2r,3e,5r)-5,6-dimethylhept-3-en-2-yl]-5,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-ol

C28H42O (394.3235)


   

2-methyl-5-(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl)cyclohexa-2,5-diene-1,4-dione

2-methyl-5-(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl)cyclohexa-2,5-diene-1,4-dione

C27H38O2 (394.2872)


   

(1r,3ar,7s,11ar)-1-[(2r,5r)-5,6-dimethylhept-3-en-2-yl]-5,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-ol

(1r,3ar,7s,11ar)-1-[(2r,5r)-5,6-dimethylhept-3-en-2-yl]-5,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-ol

C28H42O (394.3235)


   

(1r,3ar,8r,9ar,9bs,11ar)-1-[(2r,3e)-5,6-dimethylhepta-3,5-dien-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-8-ol

(1r,3ar,8r,9ar,9bs,11ar)-1-[(2r,3e)-5,6-dimethylhepta-3,5-dien-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-8-ol

C28H42O (394.3235)


   

(3s,6s,9s,14as)-9-[(2s)-butan-2-yl]-1,4,7-trihydroxy-6-methyl-3-(2-methylpropyl)-3h,6h,9h,12h,13h,14h,14ah-pyrrolo[1,2-a]1,4,7,10-tetraazacyclododecan-10-one

(3s,6s,9s,14as)-9-[(2s)-butan-2-yl]-1,4,7-trihydroxy-6-methyl-3-(2-methylpropyl)-3h,6h,9h,12h,13h,14h,14ah-pyrrolo[1,2-a]1,4,7,10-tetraazacyclododecan-10-one

C20H34N4O4 (394.258)